Evotec SE today celebrated the Grand Opening of a new facility, Building 95 (“B95”), on the Company’s Dorothy Crowfoot Hodgkin Campus at Milton Park. Evotec has had a presence in Abingdon since the Company’s acquisition of Oxford Asymmetry International plc (“OAI”) in 2000 and today is one of the largest occupiers at Milton Park. 

Evotec SE, LabCentral, a launchpad for high-potential life science and biotech start-ups, BioLabs, an international membership based network of shared lab and office facilities, and MBC BioLabs, premier providers of co-working laboratory space, today announced an agreement to boost early-stage innovations through access to Evotec’s leading shared end-to-end R&D platform. 

Evotec SE and Novo Nordisk today announced LAB eN², a translational drug discovery accelerator that aims to nurture early research from academic institutions into novel therapeutics. The focus is on addressing unmet need in cardiometabolic diseases as well as rare blood and rare endocrine disorders. LAB eN² is a unique engagement model that combines Evotec’s multimodality drug discovery and pre-clinical development capabilities with Novo Nordisk’s therapeutic, clinical, and commercial expertise. LAB eN² has already signed on four academic institutions to participate: Harvard University, Mass General Brigham, Yale University, and Beth Israel Deaconess Medical Center.

Evotec SE today announced its financial results and corporate updates for the first half-year of 2023.

Evotec SE will announce its financial results for the first half-year of 2023 on Tuesday, 29 August 2023.

Evotec today announced that its partner STORM Therapeutics Ltd. (“STORM”), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, will be presenting the discovery of its lead clinical candidate, STC-15, at the American Chemical Society (ACS) Fall 2023 Conference. STC-15, an orally bioavailable and highly selective METTL3 inhibitor, was co-designed and developed through a collaboration between STORM and Evotec.

Evotec SE today announced that it is adjusting its guidance for the fiscal year 2023 due to the impact of the cyber-attack. 

Evotec SE today announced that Bristol Myers Squibb Company has exercised its option to enter into an exclusive global licence agreement. The licence covers selected late-stage discovery programmes that were developed and progressed within the collaboration.

Evotec SE today announced that the U.S. Department of Defense (“DOD”) has awarded Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 74 m for the rapid development of monoclonal antibody (“mAb”)-based drug product prototypes targeting orthopoxviruses.

Evotec SE announced today that it is to receive a € 2 m milestone payment from Bayer AG, which is triggered by the first patient dosed in the clinical Phase I study of a kidney disease programme stemming from the Evotec-Bayer multi-target research collaboration in kidney diseases. The drug candidate, a monoclonal antibody (“mAb”) targeting the protein Semaphorin-3A (“Sema3A”) is being developed as a potential first-to-market treatment for Alport syndrome, a rare genetic kidney disease.

Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s virtual Annual General Meeting 2023 with the required majority.

Evotec SE today announced the successful arrival and start of installation of the cleanroom PODs at its J.POD biologics manufacturing facility located on Evotec’s Campus Curie in Toulouse, France. Manufactured and delivered by G-CON, a global leader in off-site pre-fabricated cleanroom systems, the cleanroom PODs will be installed over the next few weeks. G-CON previously supplied the cleanroom PODs for the first J.POD facility at Just – Evotec Biologics’ site in Redmond, WA (US) in August 2021.

Evotec SE will resume its dual listing in the German stock indices MDAX and TecDAX, following the quarterly index review of the DAX index family through Qontigo, the index operator of Deutsche Börse. The changes were announced by Qontigo after market close on 05 June and will become effective on 19 June 2023. 

Evotec SE today presents an update on the Company’s sustainability strategy and shares details on its ESG (Environmental, Social and Governance) performance towards strengthening its competitiveness and contributing to a better future for next generations to investors and interested stakeholders at its virtual Capital Markets Day.

Evotec SE today announced that the Company has received a $ 1.7 m grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing. Under the grant, Evotec aims to discover and develop RNA-targeting small molecules as potential first-in-class therapeutics against Henipaviruses.

Evotec SE today announced that new high-throughput screening (“HTS”) facilities at the Company’s headquarters in Hamburg, as well as additional equipment for investigating the safety and efficacy of new therapeutic candidates have been put into operation. Hamburg’s Senator for Economic Affairs, Dr Melanie Leonhard, visited Evotec's Manfred Eigen Campus to see how the expanded HTS facilities in combination with technologies of the future will be used to accelerate drug discovery. 

Evotec has published its Sustainability Report 2022. In reference to the GRI standards and for the first time partially audited, it is a testament to our progress made in shaping a resilient and sustainable business together with our partners, designed to cope with and to seize future opportunities from a variety of challenges today.

Evotec SE today published its Annual Report for the fiscal year 2022, as well as the qualitative Quarterly Statement for the first quarter of 2023.

Evotec SE and Sandoz AG, a division of Novartis (NASDAQ: NVS) today announced that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., launched a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars.

Evotec has been informed that Qontigo, the index operator of Deutsche Boerse, has decided to remove Evotec from MDAX and TecDAX effective 09 May. The reason for the unexpected index change was explained with the delay in the publication of the Company’s audited Annual Financial Report.

Evotec SE announced today that Cyprotex US celebrated the grand opening of its new state-of-the-art facility in Framingham, MA, today. Evotec announced the relocation of Cyprotex US, LLC to the new 30,000 square feet facility at at 200 Staples Drive in Framingham, MA in February. 

Evotec's partner Sernova, a clinical-stage company and leader in cell therapeutics, today announced the presentation of preclinical data supporting the anticipated 2024 IND submission and planned Phase 1/2 clinical trial of Evotec SE’s (FSE: EVT; NASDAQ: EVO) iPSC-derived ILCs in combination with Sernova’s implantable Cell Pouch device for the treatment of patients with T1D. The objective of the partnership is to produce an off-the-shelf, commercially scalable cell therapy treatment, with human testing anticipated to begin in 2024.

Evotec-partner Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates ("ADCs").

Dear Friends of Evotec,

We detected a cyber-attack on 6 April. I write you today from my temporary E-Mail werner.lanthaler@evotec.eu, which might appear as a sign that we are “back”, but in fact we have never been “gone”. 

Cyber-attacks are malicious acts, that we all have to accept as a new reality in business life. However, our mission research never stops (#ResearchNeverStops), also not due to cyber-attacks!

Evotec SE today announced an update on the cyber attack that was detected on 06 April, 2023. Evotec noticed unusual activity in one of the Company’s IT systems and immediately took steps to maintain IT security and remediate the impact. 

Evotec SE today reported preliminary financial results and corporate updates for the fiscal year ended 31 December 2022.

Evotec SE announced today that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb, originally signed in 2016. The initial partnership proved highly productive in generating a promising pipeline of discovery to clinical-stage programmes. Based on this success, Bristol Myers Squibb and Evotec extend and expand this partnership for additional 8 years with the goal to further broaden and deepen the strategic alliance.

Evotec SE announced today that the Company has received a US$ 6.6 m grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis (“TB”). The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the Company to progress a portfolio of TB drug discovery projects that have the potential to contribute to a universal, shorter, safer and simpler TB drug regimen.

Evotec announces that the Company has been selected as a winner of a 2023 CDMO Leadership Award across all the six core categories included in the award program including Capabilities, Compatibility, Expertise, Quality, Reliability and Service across two groups of respondents, Small Pharma, and Overall (combined Big and Small Pharma).

Evotec SE will announce its preliminary financial results for 2022 on Tuesday, 28 March 2023.

Evotec SE today announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Performance-based and programme-based achievements trigger payments of in total US$ 75 m to Evotec.

Sernova Corp., a clinical-stage company and leader in cell therapeutics, announced today that an abstract has been selected for an oral presentation at the 4^th International Pancreas and Islet Transplant Association (IPITA) / Harvard Stem Cell Institute (HSCI) / Juvenile Diabetes Research Fund (JDRF) Summit, to be held from April 24-25, 2023 in Cambridge, Massachusetts. The presentation will be given by Matthias Austen, PhD, SVP Cell Therapy at Evotec SE.

Evotec SE announced today that Cyprotex US, LLC, the US site of Cyprotex a wholly owned subsidiary of Evotec, has completed its relocation from Watertown, MA to a new state-of-the-art facility in Framingham, MA, paving the way for significant further growth of its ADME-Tox services business for US-based customers. 

Evotec SE and the European Investment Bank (“EIB”) announced today that the EIB has granted Evotec an unsecured loan facility of € 150 m to support the Company’s R&D activities, equity investments and the building of the new J.POD^® biologics manufacturing facility on Evotec’s Campus Curie in Toulouse, France. 

Evotec SE announced today that the Company has extended and expanded its integrated multi-target drug discovery agreement with data-driven biotech creation firm, Related Sciences (“RS”), to continue to grow their joint portfolio of drug development candidates through 2030, leveraging Evotec’s industry-leading capabilities across the full R&D continuum.

Evotec SE announced today that the Company's Supervisory Board has appointed Laetitia Rouxel as new Chief Financial Officer and member of the Management Board effective 01 April 2023. She will take over from Enno Spillner whose contract will expire at the end of March and who will pursue new opportunities. 

Evotec SE announced today that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration focuses on the development of first-in-class targeted immune-based therapies for oncology, which will ultimately be commercialised by Janssen. The agreement was facilitated by Johnson & Johnson Innovation.

Sernova Corp., a clinical-stage company and leader in cell therapeutics, announced today that significant progress has been achieved in its collaboration with Evotec SE. This progress includes advancement of Evotec’s iPSC derived islet-like clusters in combination with Sernova’s implantable Cell Pouch™ device toward a first-in-human Phase 1/2 clinical trial for the treatment of patients with T1D and severe hypoglycemia slated for regulatory filing in 2024.

Evotec SE announced today that the Company has achieved further significant progress within its neuroscience collaboration with Bristol Myers Squibb. The collaboration expands the portfolio by two additional drug discovery projects and has designated a target-based programme for further development, triggering payments in total of US$ 26 m to Evotec.

Evotec partner Kazia Therapeutics Limited, an oncology-focused drug development company, announced the publication of positive pre-clinical data for EVT801, a clinical-stage drug candidate currently in a clinical trial for multiple forms of cancer.

Evotec SE announced today that the Company will substantially reduce its carbon emissions by joining the renewable energy heating network Toulouse Energie Durable (“TED”). 

Evotec’s partner Exscientia plc today announced clinical trial application (“CTA”) approval of a Phase I/II trial of EXS-21546, an A2a receptor antagonist, co-invented and developed through a collaboration between Exscientia and Evotec.

Evotec SE today announced the financial results and corporate updates for the first nine months 2022. Group revenues increased by 19% (13% excluding fx-effects) to € 510.8 m (9M 2021: € 431.0 m), despite significantly lower milestones, upfronts and license payments compared to a very strong comparable basis in 2021 (9M 2022: € 8.1 m vs. € 36.5 m in 9M 2021); base business at € 502.7 m continued to show very strong growth of 27% (9M 2021: € 394.5 m).

Evotec SE announced today that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in August 2022, has been completed. 

Evotec SE will announce its financial results for the first nine months 2022 on Wednesday, 09 November 2022.

Evotec SE today presents at its Capital Markets Day an update on how the Company is taking meaningful steps to transform biologics manufacturing to enable global access.

Evotec SE today announced that the Company’s Seattle-based subsidiary, Just – Evotec Biologics, Inc. has been selected as a winner of a CPhI Pharma Award 2022. Just – Evotec Biologics entered the competition in the category “Manufacturing Technology and Equipment” with its flexible cGMP biomanufacturing plant J.POD^®. J.POD^® represents a paradigm shift in biologics manufacturing. 

Evotec SE today announced the launch of “Extend”, a translational BRIDGE partnership in cooperation with CDP Venture Capital Sgr, a strategic pillar to Italy's economic growth and innovation, and Angelini Ventures, the Corporate Venture Capital arm of the multi-business industrial group Angelini Industries.

Evotec SE announced today that the Company has entered a partnership with Hannover Medical School (“MHH”), one of the leading German universities, to generate a molecular patient database for Sjögren’s syndrome (“SjS”) and systemic lupus erythematosus (“SLE”).

Evotec SE today announced the launch of the first commercial version of its PanOmics data analysis platform PanHunter at Bio-IT World (18-19 October in Berlin, Germany). PanHunter is Evotec’s PanOmics data access and analytics platform and was developed and used successfully internally and in industry-shaping drug discovery partnerships over many years. Evotec now makes PanHunter available to collaborators and partners as a software-as-a-service (“SaaS”) product.

Evotec SE and Toronto Innovation Acceleration Partners (“TIAP”) today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner. The expansion goes along with a combined investment of US$ 14 m to expedite LAB150 programmes towards the formation of new companies.

Aurobac Therapeutics SAS (Aurobac), announced today the appointment of Florence Séjourné as Chief Executive Officer. Aurobac is a joint venture recently created by Boehringer Ingelheim, Evotec SE and bioMérieux, focusing on the development of a new precision medicine approach, from diagnosis to cure to fight Antimicrobial Resistance (AMR).

Evotec SE today announced that the U.S. Department of Defense (“DOD”) has awarded Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 49.9 m for the rapid development of monoclonal antibody (“mAb”)-based drug product prototypes targeting plague. Plague, an infectious disease caused by the bacterium Yersinia pestis (“Y. pestis”), is one of the designated targets of interest under the DOD’s Accelerated Antibodies Program.

Evotec SE today officially launched the construction of its J.POD^® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD^® Toulouse, France (EU), the second facility of its kind and the first one on European ground, will employ Just – Evotec Biologics’ flexible J.POD^® technology to deliver much-needed clinical and commercial manufacturing capacity for biologics.

Evotec SE announced today that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd.

Evotec announces that the Company has been selected as a winner of the 2022 R&D 100 Award in the following category: Software and Services for their multi-omics analysis platform EVOpanHunter.

The Project to Accelerate New Treatments for Tuberculosis collaboration announced today the execution of a joint development agreement supporting the progression of two investigational tuberculosis combination treatment regimens into phase 2 clinical development.

Evotec SE today announced its financial results for the first half-year of 2022.

Evotec SE and Alpine Immune Sciences today announced that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., expanded a multi-year partnership with Alpine for the development of a commercial process for ALPN-303.

Evotec SE will announce its financial results for the first half-year 2022 on Thursday, 11 August 2022.

The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Evotec SE announced today that after a successful call for proposals, University of Dundee has been awarded its first funding within the beLAB1407 BRIDGE initiative. beLAB1407 is a translational BRIDGE collaboration between Evotec and Bristol Myers Squibb, aiming to accelerate translational research from the UK's academic life science ecosystem. 

Evotec SE, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR). 

Evotec SE today announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed. Based out of Medolla, Italy, the cell technology company with leading edge in the field of cGMP manufacturing of cell therapies will operate as Evotec (Modena) Srl going forward.

Evotec SE announced today that a project has been selected for further development within beLAB2122, a translational BRIDGE collaboration between Evotec and Bristol Myers Squibb. beLAB2122 aims to bring together leading academic institutions from the Rhine-Main-Neckar region of Germany to efficiently advance first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects.

Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s virtual Annual General Meeting 2022 with the required majority.

A consortium of strong partners has launched the CARMA FUND I as a new vehicle for the translation of promising early-stage life-science projects: the initiators, Ascenion GmbH, a life-science focused technology transfer company of the LifeScience Foundation and the Goethe-University, Frankfurt am Main with its technology transfer company Innovectis GmbH, together with the European Investment Fund (EIF), the life science company Evotec SE and other investors. The fund will be managed by CARMA FUND Management GmbH, headed by its general partners Christian Leikert and Martin Raditsch.

Evotec SE announced today that the Company has entered a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Evotec’s innovative TargetAlloMod platforms will be evaluated to discover first-in-class novel mode of action therapeutic candidates. The agreement was facilitated by Johnson & Johnson Innovation.

Evotec’s partner Exscientia plc today announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2a receptor antagonist co-invented and developed through a collaboration between Exscientia and Evotec SE.

Evotec SE today announced the signing of a definitive agreement under which Evotec will acquire 100% of the capital of Rigenerand Srl, a leading cell technology company, for a purchase price of € 23 m. Founded in 2009 as a spin-off of the University of Modena and Reggio Emilia, Rigenerand is a pioneering company in the field of cGMP manufacturing of cell therapies. The acquisition adds a great team of cell therapy cGMP manufacturing experts to Evotec.

Evotec SE and Almirall S.A., a global biopharmaceutical company focused on skin health, announced today a multi-target alliance in Medical Dermatology. The companies aim to discover and develop novel therapeutics for severe skin diseases, including immune-mediated inflammatory conditions such as atopic dermatitis and non-melanoma skin cancer such as basal cell carcinoma.

Evotec SE and Sernova Corp., a clinical-stage company and leader in regenerative medicine cell therapeutics today announced a partnership in the field of diabetes. Both Companies will leverage their respective strengths to develop an implantable iPSC-based beta cell replacement therapy for the treatment of insulin-dependent diabetes, including type 1 and 2.

Evotec SE today announced the financial results and corporate updates for the first quarter 2022: Strong performance leads to significant revenue growth; strong momentum in all business areas; new partnerships based on data-driven precision medicine platforms; guidance for full-year 2022 confirmed

Evotec SE announced today that the Company has extended and expanded its partnership with Bristol Myers Squibb in targeted protein degradation, originally signed in 2018. The initial collaboration has proven to be highly productive in generating a promising pipeline of molecular glue degraders. Based on this success, Bristol Myers Squibb and Evotec extend and expand this partnership for an additional 8 years with the goal to further broaden and deepen the strategic alliance.

Evotec SE will announce its financial results for the first quarter of 2022 on Wednesday, 11 May 2022. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Evotec SE announced today that the Company has made a strategic equity investment in Tubulis GmbH by participating in the company’s Series B financing round. Based in Munich, Germany, Tubulis specialises in the development of antibody drug conjugates (“ADCs”) by leveraging a set of proprietary technology platforms to develop these highly targeted therapeutics against solid tumours.

Evotec, together with BEOS, the leading asset manager and project developer of corporate real estate in Germany, celebrated the ground-breaking for Evotec’s fourth building at the Manfred-Eigen-Campus in Hamburg today.

Evotec SE today reported financial results and corporate updates for the fiscal year ended 31 December 2021. Group revenues significantly exceeded the revenue target, up 23% to € 618.0 m; Base business up 18%; Adjusted Group EBITDA in line with guidance at € 107.3 m, up 1%; Unpartnered R&D expenses of € 58.1 m (2020: € 46.4 m up 25%); Very strong liquidity position with € 858.2 m in cash

Evotec SE announced today that the Company has reached another programme designation within its neuroscience collaboration with Bristol Myers Squibb triggering a payment of US$ 16 m to Evotec. The programme further adds to a fast-growing pipeline in neurodegeneration that also includes EVT8683, which entered clinical development end of 2021.

Evotec SE will announce its financial results for 2021 on Tuesday, 12 April 2022. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Evotec SE announced today that there will be two new high-throughput screening (“HTS”) facilities at the Company’s headquarters in Hamburg, as well as additional equipment for investigating the safety and efficacy of new therapeutic candidates. The research focus is on COVID-19 therapeutics and other viral diseases.

Evotec SE announced today that the Company received a € 3 m milestone payment from Bayer AG as a result of another promising small molecule from the Evotec-Bayer multi-target research alliance advancing into Phase II clinical development as a potential treatment for diabetic neuropathic pain (“DNP”).

Evotec announces that the Company has been selected as a winner of a 2022 CMO Leadership Award in the categories Expertise (Small Pharma) and Service (Overall, Small Pharma). The awards are presented by Life Science Leader and Outsourced Pharma and the research is conducted by ISR Reports’ Contract Manufacturing Quality Benchmarking annual online surveys.

The 12^th edition is dedicated to our exciting new developments in pre-clinical cellular models with a particular focus on three-dimensional (3D) cell culture platforms, including microtissues, organoids and organ-on-a-chip systems.

Evotec SE today presents at its virtual Capital Markets Day how artificial intelligence (“AI”) and machine learning (“ML”) enabled precision technologies in discovery and development processes are driving up Probability of Success (“PoS”), i.e. an increasing rate of approvals in the long-run. To leverage the power of molecular data, Evotec is launching E.MPD, the Company’s molecular patient database. E.MPD is one of the largest and highest quality molecular databases globally.

Evotec SE announced today that the Company has entered into a collaboration with the University of Bristol (“UoB”) to expand the Company’s molecular patient database in the field of kidney diseases with a focus on nephrotic syndrome. The nephrotic syndrome is a group of symptoms like proteinuria and oedema that indicate kidneys are not working properly. Diagnosis remains challenging and current treatment regimens are mostly symptomatic.

Evotec SE, together with Boehringer Ingelheim Venture Fund, and Novo Holdings REPAIR Impact Fund invested in Centauri Therapeutics Limited ("Centauri") GBP 24 m (c. US$ 32 m) Series A investment round. Founded by Animatrix Founders LLP, Centauri is an immunotherapy company focused on the treatment of infectious diseases. Additionally to the investment, Karen Lackey, Evotec's Global Head of Integrated Drug Discovery will join Centauri’s Board of Directors. 

Evotec SE has made an equity investment in IMIDomics, Inc., a privately held global biotechnology company focused on the discovery and development of new targets and medicines for the treatment of patients with immune-mediated inflammatory diseases ("IMIDs").

Evotec SE announced today that the Company plans to significantly invest in its site at Milton Park, named Dorothy Crowfoot Hodgkin Campus, to reduce the CO₂ emissions. The project will help to achieve the company’s carbon neutral targets.

Evotec announced today that the Company has entered a target and drug discovery partnership with Boehringer Ingelheim, focusing on induced pluripotent stem cell (“iPSC”)-based disease modelling for ophthalmologic disorders. Millions of people are affected by vision-related diseases worldwide, and there is a high unmet need for novel therapeutic solutions. 

Evotec SE announced today that the Company has entered into a drug discovery collaboration with Eli Lilly and Company in the field of metabolic diseases with a focus on kidney diseases and diabetes. The collaboration leverages Evotec’s extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database.

Evotec partner Celmatix, a biotechnology company focused on ovarian biology, today announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec. The milestone was triggered by Evotec and Bayer AG advancing a drug programme, centered around a novel Celmatix-identified drug target, into hit-identification.

Evotec SE announced today that the Company has expanded its neurodegeneration collaboration with Bristol Myers Squibb with the initiation of discovery and development efforts regarding a new strategy to tackle neurodegenerative diseases including Alzheimer’s through a novel approach to targeted protein degradation. Evotec receives payments totalling US$ 15 m from Bristol Myers Squibb.

Evotec SE announced today that the Company has been selected by the German Federal Ministry of Education and Research (“BMBF”) to receive a grant for the development of EVT075, a potential first-in-class immunomodulatory therapy against COVID 19. Evotec is one of three companies receiving a highly competitive grant as part of a new initiative by the BMBF to support the clinical development of novel therapeutic candidates against COVID-19.

Evotec SE today announced that the Company has received a US$ 18 m grant from the Bill & Melinda Gates Foundation for the integrated discovery and development of a novel, first-in-class programme to accelerate progress in the area of women’s health and contraceptive technology, leveraging Evotec’s integrated R&D platform.

Evotec SE and EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx’s pipeline expansion efforts by leveraging Evotec’s unique data-driven, fully integrated R&D-platform, applied across different drug modalities and therapeutic areas. This approach aims to expedite the invention and development of novel drugs and helps ensure superior translation from research ideas to safe and efficacious medicines.

Evotec SE today announced that BofA Securities and Morgan Stanley, as representatives of the several underwriters, notified Evotec of the underwriters’ exercise of their option to purchase up to 3,000,000 additional ADSs, representing 1,500,000 ordinary shares at the offering price of $ 21.75 per ADS.

Evotec SE today announced the financial results and corporate updates for the first nine months 2021: Strong operational performance leads to significant revenue growth; co-owned pipeline gaining momentum; J.POD^® Redmond (US) operational; successful Public Offering at NASDAQ (after period-end); guidance for full-year 2021 confirmed; webcast and conference Call today at 02.00 PM CET

Evotec SE announced today that the Company reached additional programme designations within its neuroscience collaboration with Bristol Myers Squibb triggering payments of in total US$ 40 m to Evotec.

Evotec SE announced today the closing of its public offering on 08 November 2021 in the United States of 20,000,000 American Depositary Shares (“ADSs”). Each ADS represents half of one ordinary share of Evotec. All ADSs sold in the offering were offered by Evotec at a public offering price of $ 21.75 per ADS.

Evotec SE will announce its financial results for the first nine months 2021 on Thursday, 11 November 2021.

Evotec SE today announced the first two projects to be developed within beLAB1407, a collaboration between Evotec and Bristol Myers Squibb to accelerate translational research from the UK's academic life science ecosystem. Only six months after signing the beLAB1407 collaboration agreement in May 2021, the first projects to be developed within this academic BRIDGE collaboration have now been identified.

Evotec SE today announced the first project to be developed within beLAB2122, a collaboration between Evotec and Bristol Myers Squibb. beLAB2122 aims to bring together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects. After signing the beLAB2122 collaboration agreement in April 2021, the first project to be developed within this academic BRIDGE collaboration has now been nominated. 

Evotec SE, today reported preliminary and unaudited results for the first nine months ended 30 September 2021.

Evotec SE announced today that it has commenced a public offering in the United States of up to 22,000,000 American Depositary Shares (“ADSs”) representing 11,000,000 of its ordinary shares pursuant to a registration statement on Form F-1, as amended, filed with the U.S. Securities and Exchange Commission (“SEC”). Evotec expects to grant the underwriters a 30-day option to purchase up to an additional 3,300,000 ADSs. The sale of the ADSs and the issuance of the underlying ordinary shares will be made under exclusion of shareholders pre-emptive rights based on Evotec’s existing authorized capital. Evotec has applied to list its ADSs on the Nasdaq Global Select Market under the symbol “EVO”.

Evotec SE announced today that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed offering and sale in the United States of shares of Evotec represented by American Depositary Shares (“ADSs”). The Registration Statement has not yet become effective and the final number of ADSs to be offered and their price have not yet been determined.

Evotec SE announced today that its collaboration with Bristol Myers Squibb has been expanded to include a new cell type, triggering a payment of $ 9.0 m to Evotec.

The 11^th edition is dedicated to our exciting new capabilities in the biologics lane of Evotec’s “Multi-modality Autobahn.” 

Evotec partner Bayer today reported more detailed results from PAGANINI, the Phase IIb dose-finding study evaluating the efficacy and safety of eliapixant in patients with refractory chronic cough (“RCC”). Eliapixant (BAY1817080) is an investigational orally administered, potent and selective P2X3 receptor antagonist derived from a former multi-target research collaboration between Bayer and Evotec. 

Evotec SE announced today that Bristol Myers Squibb Company has exercised its option to enter into an exclusive global license for EVT8683 which comes from a broader neurodegeneration collaboration. EVT8683 is a small molecule targeting a key cellular stress response that holds great promise in various neurodegenerative indications and is ready to enter clinical development. The programme originated from a phenotypic screening approach based on Evotec’s leading iPSC platform and reached IND filing within only 5 years. Under an option agreement with Celgene (which is now a Bristol Myers Squibb company), Bristol Myers Squibb has rights to additional programmes in neurodegenerative diseases.

Evotec partner Kazia Therapeutics Limited today announced that the planned phase I study for EVT801 has received full approval from L’Agence Nationale de Sécurité du Médicament et des Produits de Santé (“ANSM”), the French regulatory agency. The study is expected to open to recruitment by the end of CY2021.

Evotec SE and Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide ("ASO") therapies to address challenging or previously undruggable targets via its LNAplus™ platform, have expanded their strategic partnership in the field of ASO-based therapeutics.

Evotec SE today announced its financial results for the first half-year of 2021: Strong overall performance in the first half of 2021 gaining speed; rapid capacity build-up to foster undisputed growth and future margin expansion; registration statement for proposed offering of American Depositary Shares submitted; guidance for full-year 2021 confirmed; webcast and conference call today at 2.00 pm CEST

Evotec SE today announced the opening of the company’s late-stage clinical and commercial biologics cGMP manufacturing facility (J.POD^® 1 US) in Redmond, Washington. The innovative cGMP biomanufacturing facility is the final step in Just – Evotec Biologics’ J.DESIGN platform that integrates data analytics and machine learning through all activities involved with the discovery, development, and manufacture of biologics. This includes design of discovery libraries (J.DISCOVERY™), molecules (J.MD™), processes (JP3^®) and the manufacturing facility, J.POD^®.

Evotec spin-off company Topas Therapeutics GmbH ("Topas"), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today announced that the Company has successfully extended its Series B round with an additional € 18 m (~$ 22 m) raised, bringing the total for this financing to € 40 m. All of Topas’ existing investors participated in the extension.

Evotec SE today announced that Evotec has added significant opportunities for further, long-term growth by acquiring the Verona site from GlaxoSmithKline SpA. During a site meeting, the employees also decided on a new name for their campus. In commemoration of Italian Nobel laureate Rita Levi-Montalcini, the Verona site will be named “Campus Levi-Montalcini” going forward.

Evotec SE announced today that the Company has launched an initiative for pandemic preparedness (“PRROTECT”). PRROTECT leverages a comprehensive set of novel projects and technologies to be better prepared for and respond faster to viral pandemics of the future.

Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s virtual Annual General Meeting 2021 with the required majority. Due to the COVID-19 pandemic, this year’s Annual General Meeting again was held as a purely virtual event. 

CEBINA GmbH today announces the launch of Danube Labs, a partnership with Evotec SE to fast-track early-stage academic research to drug discovery and development. The joint project, financed by a dedicated group of private investors, will identify, and develop academic projects into mature therapeutic product development opportunities, primed for biotech company formation or partnering.

Autobahn Labs, an early-stage drug discovery incubator, today announced a new strategic venture collaboration with Cold Spring Harbor Laboratory (CSHL). Together with Autobahn Labs, CSHL will identify promising research programs with therapeutic potential and partner to form promising new drug discovery companies.

Evotec SE today announced the financial results and corporate updates for the first quarter 2021. Group revenues from contracts with customers increased by 11% to € 133.1 m (Q1 2020: € 119.4 m); Base business growth of 28%, adjusted for the end of the Sanofi payment (since April 2020) and unfavourable fx effects; EVT Execute revenue growth of 16% (11% adjusted for material recharges) to € 136.9 m (Q1 2020: € 118.2 m), EVT Innovate revenues up 21% (20% adjusted for material recharges) to € 28.2 m (Q1 2020: € 23.3 m)

Evotec SE announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of Evotec’s drug discovery and development platforms and early-stage therapeutic concepts from the Universities of Birmingham, Edinburgh, Nottingham, and Dundee, beLAB1407 offers a unique route to the advancement of first-in-class therapeutics and the creation of spin-out companies.

Evotec SE and the University Hospital Erlangen today announced a partnership regarding molecular analyses of biospecimens from the German Chronic Kidney Disease (“GCKD”) cohort study. Under the agreement, the research team will make use of Evotec’s proprietary EVOpanOmics and EVOpanHunter platforms to facilitate deep molecular profiling of patient samples. The Evotec platforms combine enhanced throughput proteomics, high-throughput transcriptomics and integrated data analysis. 

Evotec SE will announce its financial results for the first quarter of 2021 on Tuesday, 11 May 2021. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Evotec SE today announced that Bristol Myers Squibb has decided to exercise their option to extend its partnership with Evotec in the field of targeted protein degradation. Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated this strategic drug discovery and development partnership in 2018 with the goal to identify first-in-class drug candidates initially focusing on solid tumours.

Evotec SE announced today that the Company has invested into OxVax, a new immuno-oncology company based on research from Oxford University, which enables the development of the next generation of cancer vaccines with the potential to overcome the limitations of the current approaches.

Evotec SE today announced that the Company has initiated the construction of its J.POD^® 2 EU biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD^® 2 EU, Evotec’s second innovative cGMP biomanufacturing facility, will employ Just – Evotec Biologics’ cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations housed inside autonomous cleanrooms.

Evotec SE announced today that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec’s oncology project EVT801.

Evotec SE announced today that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company. beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects.

Evotec SE today announced the most advanced asset arising from their joint venture with Exscientia has entered human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed between Exscientia and Evotec, including application of Exscientia’s next generation 3-D evolutionary AI-design platform, Centaur Chemist^®. The drug candidate has potential for best-in-class characteristics, with high selectivity for the target receptor, bringing together potential benefits of reduced systemic side effects as well as minimal brain exposure to avoid potential undesired centrally-mediated side effects.

Knowledge sharing within the scientific community is a key focus for Evotec. Sharing resources will help to collectively advance R&D and accelerate innovation - ultimately leading to new technology and therapies reaching the market faster. 

Very strong financial results: 12% increase in Group revenues beating guidance despite pandemic; unique innovation platforms and infrastructure support long-term growth in all modalities; solid balance sheet, strong foundation for next expansion steps

Evotec SE today announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.

Evotec SE will announce its financial results for 2020 on Thursday, 25 March 2021. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Evotec announces that the Company has been selected as a winner of a 2021 CMO Leadership Award in the categories Compatibility (Big Pharma), Expertise (Big Pharma), and Service (Overall, Small Pharma)

Just – Evotec Biologics’ Redmond, Washington site offers true meaning to “Facility of the Future” with flexible and podular manufacturing of clinical and commercial-stage biologics.

Argobio SAS, a newly-created start-up studio dedicated to life sciences, today announced its launch with 50 M€ of committed capital. Argobio was initiated by Kurma Partners, a leading Paris and Munich-based healthcare venture capital firm, and Bpifrance, the French national investment bank. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, internationally renowned center for biomedical research. 

Evotec SE and Chinook Therapeutics, Inc. today announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases (“CKD”). Based on Evotec’s proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterise and validate novel mechanisms and discover and develop precision medicines. 

Evotec SE announced today that the Company has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period.

Evotec SE today announced that the Company has entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf (“UKE”) for the development of a highly innovative first-in-class cell therapy approach for the treatment of heart failure.

Many of you have been asking us about the Coronavirus and its potential impact on Evotec and its affiliates. At Evotec, we are actively managing our operations to maintain business continuity while taking measures to protect the health and wellbeing of our employees, their families and the local communities in which they live and work. We have taken a number of steps to ensure the continued health and safety of our colleagues and prepare our business during this challenging time.

Evotec today announced that Dr Cord Dohrmann has been appointed to the German Council of Science and Humanities (German: “Wissenschaftsrat”) for a term of three years. He is appointed by the Federal President Frank-Walter Steinmeier on the joint recommendation of the German Federal Government and the governments of the German states.

Evotec SE today announced that EVT894, a monoclonal antibody to treat and potentially prevent chikungunya virus infections, has entered clinical development. 

Evotec SE today announced that the U.S. Department of Defense (“DOD”) awarded its Seattle, Washington-based subsidiary, Just – Evotec Biologics, Inc., an agreement worth $28.6 million for the production of monoclonal antibodies (“mAbs”) for use in the development of a treatment and/or prophylaxis for COVID-19.

Evotec SE announced today that its management will be presenting at and attending the following upcoming conferences in the first quarter of 2021:

Evotec SE announced today that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company (NYSE:BMY) within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio.

Evotec SE and Alloy Therapeutics, a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all, today announced that the companies have entered into a technology partnership to expand Evotec’s antibody discovery platform.

Autobahn Labs, a virtual incubator partnering with top academic and research institutions to catalyze early-stage drug discovery and development, today announced a strategic collaboration with the University of California San Francisco (UCSF). The organizations will partner to identify promising early science with significant therapeutic potential, forming jointly owned ventures to accelerate the translation of scientific ideas to novel therapeutics.

Evotec SE today announced that the Company has achieved key milestones in its partnership with Bristol Myers Squibb in the field of targeted protein degradation with the first two targets transitioning into drug discovery after completing a comprehensive target validation process.

Evotec SE and the life science company Sartorius announced today that they have entered into a partnership with the recently established Curexsys GmbH, a Goettingen, Germany-based technology leader specialising in the emerging field of therapeutic exosomes.

The 10th edition is dedicated to our newly developed next generation transcriptomics toxicology platform, a truly translational project across different groups at Evotec.

Evotec SE today announced a new multi-year drug development partnership with Rappta Therapeutics, a Finland-based biopharmaceutical company, focused on an innovative oncology target. 

Recorded webcast now available

Evotec SE announced today that, as part of its ongoing collaboration with STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, STORM has selected STC-15 as a first-in-class development candidate. STORM will now use INDiGO, Evotec’s unique integrated, accelerated IND-enabling platform, to progress STC-15 towards an IND application in 2021.

MULTIPLE NEW & EXTENDED DRUG DISCOVERY AND DEVELOPMENT ALLIANCES; VERY GOOD PROGRESS IN CO-OWNED PIPELINE; INCREASING MOMENTUM DESPITE DIFFICULT BUSINESS ENVIRONMENT; GUIDANCE FOR FULL-YEAR 2020 CONFIRMED; CAPACITY EXPANSION ON TRACK FOR SWIFT START TO 2021

Evotec SE today announced the expansion of the Company’s existing campus based at Milton Park in Abingdon, Oxfordshire, UK, into a major, fully-integrated, co-located discovery and development centre to be named Dorothy Crowfoot Hodgkin Campus. Adding a new building, which will house up to 100 biologists by the end of the year, will bring together all the key functions for cutting-edge and high-performance small molecule discovery and up to commercial development.

Evotec SE will announce its financial results for the first nine months of 2020 on Thursday, 12 November 2020. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English

Evotec SE announced today that its management will be presenting at and attending upcoming conferences until the end of 2020.

Eternygen today announced the first closing of its Series A2 funding round led by new anchor investor Evotec SE and additional funding from venture capital firms Epidarex Capital, IBB Ventures and a number of family offices. The new investment amounting to € 5 m will be used to drive Eternygen’s development of novel treatments for non-alcoholic steatohepatitis ("NASH") to the next milestone, i.e. the selection of a preclinical development candidate, the initiation of IND enabling studies as well as growing clinical capabilities within the team.

Evotec SE today announced that its Seattle-based subsidiary, Just – Evotec Biologics, Inc., received a grant from the Bill & Melinda Gates Foundation (Seattle, WA) as part of the COVID-19 Therapeutics Accelerator to enable the development and production of monoclonal antibody (“mAb”) candidates for the prevention of severe COVID-19 in vulnerable populations in low and middle income countries.

Topas Therapeutics GmbH, a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, today announced the successful closing of a € 22 m (~US$ 26 m) Series B financing round.

Evotec SE today announced that it resolved a capital increase from its authorised capital without pre-emptive rights against cash. Evotec will issue a total of 11,478,315 new shares to Mubadala Investment Company and Novo Holdings A/S, increasing Evotec’s cash reserves by € 250 million in total.

Evotec SE announced today that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company following the decision to expand the portfolio by another drug discovery project.

Evotec SE and the French-based BIOASTER Technological Research Institute today announced that they have entered into a partnership to advance research for infectious diseases. BIOASTER is a technology and innovation hub located in Lyon, France that has created a new model to address the latest challenges in the microbiology field, including antimicrobial resistance and vaccine safety and efficacy.

Evotec, a leading drug discovery alliance and development partnership company, has taken additional office and laboratory space at Milton Park, one of the leading science and technology communities in Europe, to bring its total occupation to 192,745 sq ft making it one of the largest occupiers on the Park.

Evotec SE today announced a partnership agreement with the University of Oxford regarding access to biospecimens from the biobank Quality in Organ Donation (“QUOD”), an initiative of The Nuffield Department of Surgical Sciences (“NDS”) at the University of Oxford in close collaboration with the National Health Service Blood and Transplant (“NHSBT”) organisation in the UK.

Evotec SE and CENTOGENE N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that the companies have expanded their existing drug discovery partnership related to the protein target glucocerebrosidase (“GBA”) with a focus on Gaucher disease, a genetic and relatively common lysosomal storage disorder. The parties intend to develop a treatment option for the majority of patients whereas currently available treatments are individualised for each patient depending on the type of Gaucher disease, focusing on symptomatic relief.

Evotec SE and Novo Nordisk today announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease. Evotec and Novo Nordisk will jointly identify and develop novel targets based on comprehensive medical and molecular data sets of thousands of chronic kidney disease patients. The collaboration intends to pursue the most relevant human disease biology in a therapeutic modality-agnostic approach to develop first-in-class therapeutics for patients suffering from CKD.

Evotec SE today announced its financial results for the first half-year of 2020: Significant Group revenue growth of 12% to € 231.0 m (H1 2019: € 207.1 m); Revenue growth in both business segments: EVT Execute revenues up 16% to € 228.2 m (H1 2019: € 196.8 m); EVT Innovate revenues up 8% to € 44.6 m (H1 2019: € 41.2 m); Adjusted Group EBITDA amounting to € 47.3 m (H1 2019: € 58.2 m)

Evotec SE announced today that the Company has entered into a new partnership with the Biotech company Resolute Therapeutics (“Resolute”) to combat infectious diseases and antimicrobial resistance. The partnership aims to develop a broad-spectrum antibiotic with a new mode of action compared to antibiotics currently on the market and will receive substantial funding from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership led by Boston University and dedicated to funding and supporting the development of therapeutics, vaccines and rapid diagnostics to address the most serious drug-resistant bacteria.

Evotec SE and the leading independent European antisense drug discovery company, Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), today announced a strategic partnership in the field of antisense oligonucleotide (“ASO”)-based therapeutics. Antisense therapy is an innovative, clinically and commercially validated, highly-targeted pharmacological approach which interferes with gene expression in the cells of interest to specifically inhibit the production of proteins which promote development and progression of diseases. 

Evotec SE will report its financial results for the first half-year of 2020 on Wednesday, 12 August 2020. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for the fiscal year 2020. The conference call will be held in English.

Evotec SE today announced that the U.S. Department of Defense (“DOD”) awarded its Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 18.2 m to develop and manufacture monoclonal antibodies (“mAbs”) for treatment and/or prevention of COVID-19. The goal of this programme is to rapidly and efficiently deliver the mAbs to the DOD.

Evotec SE announced today that the Company has entered into a comprehensive partnership with the recently established QUANTRO Therapeutics GmbH (“QUANTRO”), a research-based biotech company based in Vienna, Austria, that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programmes in cancer and other diseases.

Evotec SE today announced that Evotec has added significant opportunity for further, long-term growth of its Toulouse-based operations by taking over “Biopark by Sanofi”.

 The 9th edition of DDup is dedicated to our unique and innovative iPSC-based drug discovery programme TargetRD (Retinal Disease), which we have developed in collaboration with our colleagues from the Centre for Regenerative Therapies TU Dresden.

Evotec SE, Samsara BioCapital, a leading life sciences investment firm, and KCK Ltd., a family investment fund, today announced the launch of Autobahn Labs, a novel virtual incubator partnering with top academic and research institutions to catalyse early-stage drug discovery and development. 

Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s virtual Annual General Meeting 2020 with the required majority. Due to the COVID-19 pandemic, this year’s Annual General Meeting was held as a purely virtual event. 

Evotec SE today announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has entered into an agreement with Advanced BioScience Laboratories, Inc. (“ABL”), a global contract development and manufacturing organisation (“CDMO”) to the U.S. Government and biopharmaceutical industry.

Evotec SE today announced that its wholly owned subsidiary Cyprotex US, LLC has been awarded a new 5 year contract with the US Environmental Protection Agency (“EPA”). The project forms part of the EPA’s Computational Toxicology and Exposure Research efforts (“CompTox”) whose goal is to provide solutions-driven research to rapidly evaluate the potential human health and environmental risks due to exposures to environmental chemicals. 

Evotec SE today announced that the Company has participated in the Series C funding round of Exscientia, the world-leading Artificial Intelligence (“AI”)-driven drug discovery company. The funding round led by new investor Novo Holdings raised $ 60 m with the existing investors’ consortium consisting of Evotec, Bristol Myers Squibb, and GT Healthcare Capital also participating in the round.

Evotec SE today announced the financial results and corporate updates for the first quarter 2020. 15% increase in group revenues from contracts with customers to € 119.4 m; Strong revenue growth in both segments: EVT Execute revenues up 18% to € 118.2 m (Q1 2019: € 100.3 m), EVT Innovate revenues up 24% to € 23.3 m (Q1 2019: € 18.8 m); Stable adjusted Group EBITDA of € 30.0 m (Q1 2019: € 30.0 m); adjusted EBITDA of € 35.4 m for EVT Execute (Q1 2019: € 32.2 m); No material impact by COVID-19 pandemic on financial development so far 

Evotec SE and its collaborators Toronto Innovation Acceleration Partners (“TIAP”) and AmorChem Therapeutics today announced a $ 1.75 m investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide.

Evotec SE will report its financial results for the first quarter of 2020 on Thursday, 14 May 2020. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for the fiscal year 2020.

Evotec SE today announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has entered into a partnership with Ology Bioservices, Inc. (“Ology Bio”) for the evaluation and analytical characterisation of antibodies against SARS-CoV-2.

Evotec SE announced today that it will regain global development and commercialisation rights to the iPSC-based programme for the treatment of diabetes developed under collaboration agreement with Sanofi. 

Evotec SE today announced a strategic partnership and equity investment with leon-nanodrugs GmbH (“leon”). Based in Munich, Germany, leon is the leading enabler of nanotechnology for the pharmaceutical industry. Under the terms of the agreement, Evotec and leon will cooperate on selected development programmes and maximise the effectiveness of clinical and commercial nanomedicines.

Just – Evotec Biologics announced today that the Company has compiled a library of a new class of humanoid antibodies using a novel, AI-derived approach. Antibodies are proteins produced and secreted by B-cells. As they bind to foreign substances that invade the body, such as pathogens and a plethora of other targets, they represent an important class of biologics-based therapeutics.

Evotec SE today announced that the Company has established a dedicated site for research and development of gene therapy-based projects: Evotec Gene Therapy (“Evotec GT”) which will start operations with a strong team of gene therapy experts at an R&D site in Orth/Donau, Austria.

Evotec SE today announced that Evotec GT, with operations in Austria, has established a long-term research alliance with Takeda to support Takeda’s growing number of research stage gene therapy discovery programmes. Evotec GT is an integral part of Evotec’s integrated fully modality-agnostic drug discovery platform that combines all activities involved with the discovery, development, and manufacturing of therapeutics along the value chain. 

Evotec SE and the innovative biotechnology company panCELLa Inc. announced today that the companies have entered into a licensing and investment agreement. Under the terms of the agreement, Evotec will receive a non-exclusive licence to access panCELLa’s proprietary iPS cell lines “iACT Stealth Cells™”, which are genetically modified to prevent immune rejection of derived cell therapy products (“cloaking”). 

Evotec SE announced today that the Company has entered into a strategic collaboration with Ildong Pharmaceutical Co., Ltd. (“Ildong”), a leading pharmaceutical company in South Korea, to accelerate the development of several of Ildong’s proprietary projects through access to Evotec’s INDiGO platform.

Evotec SE today reported financial results and corporate updates for the fiscal year ended 31 December 2019. Group revenues up 19% to € 446.4 m, adjusted Group EBITDA up 29% to € 123.1 m, unpartnered R&D expenses of € 37.5 m, liquidity position more than doubled to € 320.0 m.

Evotec’s partner Forge Therapeutics, Inc. (“Forge”) today announced a research collaboration and option agreement with Hoffmann-La Roche Ltd. (“Roche”) to license one of its novel antibiotics for the treatment of hospital-based lung infections. The targeted infections includes those cited on the CDC’s most urgent threats list, which commonly occur in people with weakened immune systems and chronic lung diseases.

Evotec SE will report its financial results for 2019 on Thursday, 26 March 2020. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2020.

Today a consortium of philanthropic, non-profit and private sector organizations launched a collaboration that aims to accelerate the development of novel “pan-TB” drug regimens for the treatment of tuberculosis (TB) that are ready for phase 3 development. The regimens will be designed to have little to no drug resistance and an acceptable safety profile, and be better-tolerated, shorter in duration and simpler to use than existing options. Such regimens are intended to be a central component of efforts to address the current complexities and challenges of TB treatment.

The exact number of women suffering from endometriosis is unknown. However, it is estimated that 10% of women worldwide are affected. Endometriosis is a debilitating disease in which the endometrial cells that usually line the uterus are found in other regions of the body.

Evotec SE announced today that its partner Bayer AG has decided to advance a further programme from the endometriosis multi-target alliance into clinical Phase I development.

Evotec SE and Indivumed today announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (“NSCLC”).

Evotec SE today announced that its wholly-owned Seattle-based subsidiary company Just – Evotec Biologics, Inc. has established a collaborative relationship with OncoResponse, Inc., a biotech company developing human antibodies as product candidates for multiple high value targets associated with immunosuppressive myeloid biology.

Evotec SE today announced that the wholly-owned Seattle-based company Just – Evotec Biologics initiated the construction of a late-stage clinical and commercial manufacturing facility for biologics in Redmond, Washington.

Evotec SE today announced that its wholly-owned Seattle-based subsidiary company Just – Evotec Biologics, Inc. has expanded its collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, regarding the development of innovative technologies for the production of biologics of the highest quality.

Evotec SE and Bayer AG today announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”).

Evotec SE announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company following the decision to expand the collaboration to include additional cell lines.

Evotec SE announced today that its management will be presenting at and attending investor conferences in January and February 2020.

Evotec SE today announced successful achievement of a third milestone in their diabetes research alliance with Sanofi, resulting in a payment of € 3 m to Evotec. This milestone was triggered after Evotec met pre-agreed critical criteria within the beta cell replacement therapy programme.

Evotec SE today announced plans to extend its sample management activities through an expansion of its service agreement with Sanofi. Under the terms of the new agreement, Sanofi will transfer its liquid compounds to Evotec in Toulouse over the next 2 years.

Evotec spin-off Topas Therapeutics GmbH (“Topas”), a Hamburg, Germany-based private platform company leveraging the natural tolerance induction capabilities of the liver, today announced that the first patient has been enrolled in a first-in-human Phase 1 trial evaluating TPM203 in patients with pemphigus vulgaris ("PV"), an orphan autoimmune disease. 

Toronto Innovation Acceleration Partners ("TIAP") announced today the launch of a new project developed under the BRIDGE LAB150, a partnership between Evotec SE and TIAP. The project will be focusing on breakthroughs in novel cellular drug screening systems in oncology-focused scientific KRAS research by Professor Igor Stagljar at the University of Toronto, a TIAP Member, and aims to develop therapeutics targeting the protein-protein interactions of KRAS and its downstream interacting partners.

New medicines for treating tuberculosis, malaria and other infectious diseases are still urgently needed, particularly in developing countries. The spread of antibiotic-resistant germs also results in a critical shortage of effective medications for treating and containing infectious diseases. Although this is a global problem, developing and emerging countries are particularly affected.

Evotec SE today announced an expansion of the Company’s strategic partnership with Celmatix Inc., the leading precision health company advancing the fields of reproductive medicine and fertility at the intersection of big data and genomics. 

The biologics industry is growing at an incredible rate. While its global market value was estimated at $ 236 bn in 2017, it is expected to rise to $ 310 bn by 2023. As key market players enter the field, competition is increasing.

Immunitas Therapeutics, a single cell genomics-based drug discovery company founded by Longwood Fund, today announced a $39 million Series A financing led by Leaps by Bayer and Novartis Venture Fund and joined by additional investors including Evotec, M Ventures, Alexandria Venture Investments, and other institutional investors.

Evotec SE announced today that its management will be presenting at and attending upcoming conferences in November and December 2019.

Evotec SE today reported financial results and corporate updates for the first nine months ended 30 September 2019.

Merck today announced that it has signed a license agreement providing Evotec SE access to Merck’s foundational CRISPR intellectual property.

Evotec SE and Vifor Pharma today announced the launch of a 50:50 joint venture focused on the discovery and development of novel nephrology therapeutics. Vifor Pharma will be benefiting from access to an external R&D capability for the development of its own nephrology pipeline, while Evotec will gain access to a commercial partner through outlicensing all nephrology assets developed through the joint venture to the Vifor Pharma Group.

Evotec SE will announce its financial results for the first nine months of 2019 on Tuesday, 12 November 2019. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Evotec SE today announced the inauguration of LAB555, an academic BRIDGE partnership with Integra Holdings and Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem.

Evotec SE and Biocon Limited today announced that Biocon Biologics, a wholly owned subsidiary of Biocon Ltd, and Just – Evotec Biologics, wholly owned by Evotec, have entered into a strategic licensing agreement for an early-stage, pre-clinical biosimilar asset.

Evotec SE and Celmatix Inc., a precision medicine company with a proprietary multi-omics platform, today announced a partnership to develop pre-clinical programmes in prevalent but underserved conditions affecting women’s reproductive health, including polycystic ovary syndrome (“PCOS”), endometriosis, and infertility.

Evotec SE today announced that the Company has reached a milestone in a drug discovery and development partnership with the biopharmaceutical company Aeovian Pharmaceuticals, Inc. (“Aeovian").

Evotec SE and Indivumed GmbH announced today that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer.

Evotec SE today announced a strategic, multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). Under the collaboration, the parties aim to establish at least five drug discovery programmes with the goal of Evotec delivering clinical candidates for Takeda to pursue into clinical development.

Evotec SE announced today that its management will be presenting at and attending investor conferences in September and October.

Evotec SE today reported financial results and corporate updates for the first half of 2019. Group revenues up 16% to € 207.1 m (H1 2018: € 178.9 m). Adjusted Group EBITDA up 51% to € 58.2 m (H1 2018: € 38.6 m). Unpartnered R&D expenses of € 18.7 m (H1 2018: € 10.0 m). Strong liquidity position of € 341.8 m (31 December 2018: € 149.4 m) following issue of € 250 m promissory note (Schuldschein) and final repayment of € 140 m acquisition bridge facility.

Evotec SE will report its financial results for the first half of 2019 on Wednesday, 14 August 2019.

Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel antibacterial agents today: Gram-Negative Antibacterials NOW (“GNA NOW”).

Evotec SE today announced that the Company has been notified by its partner Bayer about the successful outcome of a combined Phase I/IIa study with the P2X3 antagonist BAY1817080, originating from the Evotec/Bayer multi-target alliance. 

Evotec SE today announced that the Company has acquired assets from the stem cell specialist Ncardia AG to advance Evotec’s iPSC platform, one of the leading iPSC-based discovery platforms in the industry. 

Evotec SE today announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers. Breakpoint Therapeutics’ mission is to develop first and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of therapy-resistant cancers.

Evotec SE today announced that the strategic transaction to acquire Just Biotherapeutics (“Just.Bio”), signed on 20 May 2019, has been completed. The acquisition accelerates Evotec’s long-term strategy to be the industry partner of choice for external end-to-end innovation, strengthening Evotec’s multimodality approach to R&D. Evotec acquired Just.Bio to integrate their cutting-edge machine-learning technologies and agile, flexible methods for the design, development, and manufacturing of biologics into Evotec’s drug discovery offerings.

Just Biotherapeutics, Inc., an integrated design company focused on technologies for accelerating the development and manufacture of biotherapeutics, announced today that they have entered into an agreement with Teva for the design and development of a high productivity (HP) biomanufacturing process.

Evotec SE announced today that the Company successfully issued a Schuldschein (promissory note) of € 250 m on the capital market. The Schuldschein was placed with a fixed and variable interest rate of on average below 1.5 percent over 3, 5, 7, and 10 years maturity. Following high demand from debt investors, which led to a significant oversubscription of the order book and attractive credit spreads, the initial target volume of € 100 m could be successfully increased to € 250 m.

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it has entered into a new strategic partnership with the British clinical AI technology company Sensyne Health plc (LSE:SENS) (“Sensyne”), the University of Oxford, Oxford University Innovation Ltd (“OUI”, the university's research commercialisation company), and Oxford Sciences Innovation (“OSI”, the world's largest IP investment company dedicated to a single university) to fund a new BRIDGE called LAB10x. 

Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2019 with very strong supporting majorities.

MaRS Innovation has announced the launch of a fifth project to be developed under the BRIDGE LAB150, a partnership between Evotec SE and MaRS Innovation. The aim of the project is to develop a novel rapid-acting antidepressant with the potential to provide patient relief much faster than conventional treatments.

Evotec SE today announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis (“TB”), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide. The current standard treatment regimen for TB consists of a minimum of 6 months of treatment with 4 drugs administered under direct observation, but treatment is much longer when TB is drug resistant.

Evotec SE announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. 

The 8th edition of DDup is dedicated to our highly innovative iPSC platform, which we started developing more than six years ago with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach highest industrial standards. Today, it represents one of the largest and most sophisticated iPSC platforms in the industry.

Evotec SE announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”), for up to $ 90 m including potential performance-based earn-out components expected within the next three years.

Evotec SE announced today that its management will be presenting at and attending the following upcoming conferences:

Berenberg Conference USA 2019, Tarrytown, NY, USA

2019 RBC Capital Markets Global Healthcare Conference, New York, NY, USA

dbAccess Berlin Conference 2019, Berlin, Germany

Jefferies 2019 Healthcare Conference, New York, NY, USA

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today reported financial results and corporate updates for the first quarter of 2019.

Evotec SE will report its financial results for the first quarter of 2019 on Tuesday, 14 May 2019. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2019. The conference call will be held in English.

Evotec SE today announced that it has completed the repayment of the € 140 m debt bridge facility Evotec drew down in context of the acquisition of Aptuit in 2017. Effective August 2017, Evotec acquired Aptuit, a partner research organisation for integrated outsourced drug discovery and development, for € 253.2 m in cash. This acquisition was financed through existing cash reserves and a new € 140 m senior debt bridge facility.

Evotec SE and Indivumed GmbH announced today that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”). The collaboration, which runs for an initial term of two years, will combine Evotec’s proprietary bioinformatics analysis platform “PanHunter” as well as its small molecule and antibody discovery platforms with the CRC cohort of Indivumed’s true multi-omics cancer database “IndivuType”. The goal of this precision medicine collaboration is to deliver highly effective and durable treatments with clear strategies for CRC patient stratification.

Evotec SE announced today that it has completed its conversion into a company under European law (Societas Europaea, “SE”) with its registration in the commercial register of the District Court of Hamburg. It will operate under the registered name Evotec SE with the commercial register number HRB 156381 effective immediately and its headquarters will remain in Hamburg. The new legal form has no impact on the Company’s day-to-day operations.

Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2018.

Evotec AG and The Mark Foundation for Cancer Research today announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics in oncology. The collaboration, for an initial period of two years, is based on Evotec’s new proprietary drug discovery platform TargetAlloMod, which is focused on disrupting cell signalling via a novel mechanism of action. This approach is expected to deliver highly potent and more durable treatments for both clinically validated and novel immuno-oncology targets.

Evotec's partner Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered a three-year AI drug discovery partnership with leading biopharma company Celgene, including an initial $ 25 million upfront payment and eligibility to receive substantial milestones based on the clinical, regulatory and commercial success of the program.

Evotec AG will report its financial results for 2018 on Thursday, 28 March 2019. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2019. The conference call will be held in English.

Evotec AG and The Global Antibiotic Research and Development Partnership (“GARDP”) are today announcing the formation of a new strategic public-private partnership to tackle the growing threat of antimicrobial resistance (“AMR”). By joining forces, Evotec and GARDP will leverage their capabilities and networks to address drug-resistant bacterial infections. This includes bringing together GARDP’s clinical expertise and sustainable access commitment with Evotec’s leading drug discovery platform, expertise in medicinal chemistry and pharmacology, as well as its world-leading collection of bacterial pathogens.

Evotec AG announced today that its management will be presenting at and attending the following upcoming conferences: BioCapital Europe, Bankhaus Lampe Deutschlandkonferenz, H.C. Wainwright Global Life Sciences Conference, Kempen & Co Life Sciences Conference.

Evotec AG announced today that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough. As a result of the trial initiation, Evotec received a payment of € 3 m. In October 2012, Evotec and Bayer began their multi-target discovery alliance with the shared goal to discover three clinical candidates with a focus in the field of endometriosis. The successful and productive long-term alliance ended in 2018, generating six first-in-class pre-clinical candidates three of which have progressed into Phase I clinical trials.

MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both of which are Members of MaRS Innovation. The projects aim to develop novel therapeutics for the treatment of cystic fibrosis and of respiratory syncytial virus, respectively. 

Evotec AG and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics that overcome drug-resistant bacterial pathogens. Research activities will initially be focused on the optimisation of cystobactamids, a family of natural antibacterial products with innovative chemical scaffolds that are active against the most dangerous Gram-negative pathogens on the WHO priority list.

Evotec AG and Galapagos NV today announced a global collaboration focused on a novel target for fibrosis and other indications. The collaboration concerns a small molecule programme, currently in pre-clinical development for the treatment of fibrotic diseases of the liver and other organs. The target has been identified and validated using Evotec’s proprietary platforms for fibrotic diseases and NASH. Evotec utilised its in-house assay development and drug screening capabilities to identify small molecule modulators against the target, which remains undisclosed.

Evotec AG mourns the loss of Nobel laureate and Company co-founder Prof. Manfred Eigen, who passed away on 06 February at the age of 91.

Evotec AG announced today that it has earned a $ 2 m milestone payment from Second Genome, Inc., a leading microbiome science-based discovery & development company, for the initiation of a Phase II clinical study of SGM 1019, a first-in-class oral therapeutic for the treatment of nonalcoholic steatohepatitis (NASH). The Phase II trial of SGM-1019 has been initiated following the completion of two successful Phase I trials.

Evotec AG announced today that Cyprotex, an Evotec Company, will participate in the new European collaborative project SCREENED which aims to develop new 3D in-vitro tests to overcome limitations of existing tests. SCREENED aims to develop three-dimensional (3D) cell-based in vitro tests to better characterise the effects of endocrine disruptors on thyroid gland function. This method will overcome the limitations of existing tests, being more sensitive at low doses of exposure to chemicals, and enabling the prediction of their toxicity on human health in a sex-specific manner.

Evotec AG announced today that its strategic alliance with Celgene Corporation (“Celgene”) has reached another important scientific achievement, resulting in Celgene designating a programme and triggering a payment of $ 14.0 m to Evotec. The payment was received by year-end 2018. This scientific achievement was the advancement of a programme into the lead optimisation stage developed from Evotec’s compound library using its induced pluripotent stem cell (“iPSC”)-based screening platform. This programme can be further optimised and progressed towards IND-ready status.

Evotec AG announced today an additional investment of approximately $ 6 m towards Exscientia’s latest funding round (Series B). Exscientia, the world-leading Artificial Intelligence (AI)-driven drug discovery company, has raised $ 26 m in a Series B financing round. Celgene Corporation and GT Healthcare Capital Partners joined as new investors and Evotec, previously the only large external investor, fully participated in this round.

Evotec AG  announced today that its management will be presenting at and attending upcoming conferences:

Evotec AG today announced that its partner Forge Therapeutics has received a second award from CARB-X (Combating Antibiotic Resistant Bacteria) for developing a novel antibacterial therapeutic agent. 

Evotec AG announced today that its management will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, USA.

Evotec AG today announced a new integrated drug discovery alliance with LEO Pharma, a global leader in medical dermatology. The collaboration goal is to generate new leads against innovative targets for a range of dermatological conditions and initially runs for two years. The collaboration leverages Evotec’s industry-leading hit identification platform including the extensive screening, structural biology and fragment-based drug design capabilities and expertise together with LEO Pharma’s 110-year track record of drug development and advancing science in dermatology.

Evotec AG announced today that the company won the Scrip Award 2018 for “Business Development Team of the Year”. This particular award recognises the achievements of Evotec’s Business Development Team over the last year, which has been characterised by many new alliances and partnerships between Evotec and partners from the pharmaceutical and biotech industry as well as academic institutes.

LAB282, a unique funding-expertise hybrid model to accelerate Oxford therapeutics out of the lab and into the wider world, launched two years ago this month.

Read about what it’s achieved so far, and what’s next for the partnership.

Evotec AG today announced that it has entered into a research collaboration with Immuneering Corporation (“Immuneering”), a worldwide leader in data-driven drug discovery, to discover novel small molecules for rare hereditary metabolic diseases. The research collaboration brings together Evotec’s leading induced pluripotent stem cell (“iPSC”) platform and broad drug discovery capabilities with Immuneering’s unique Artificial Intelligence-driven drug discovery platform to accelerate ligand identification for novel targets.

Evotec AG today reported financial results and corporate updates for the first nine months of 2018: Strong operational and scientific performance; 57% increase in group revenues, 77% increase in adjusted group EBITDA; Strong outlook for 2018 confirmed and good underlying business indications for 2019; Webcast and conference call today at 02.00 pm CET

Evotec AG announced today that the company has won one of the prestigious “Technology Fast 50” awards with which Deloitte honours the fastest-growing innovation drivers within the technology sector. At yesterday’s award ceremony, Evotec received the prize for “Sustained Excellence” which recognises the Company’s long-term growth, innovation capability, entrepreneurial spirit, as well as its sustainable corporate management.

Evotec AG announced today that its management will be presenting and attending the following upcoming conferences:

Jefferies London Healthcare Conference 2018, London, UK

15th Kempen London Conference, London, UK

German Equity Forum 2018, Frankfurt am Main, Germany

16th Berenberg European Conference, Surrey, UK

Evotec AG will report its financial results for the first nine months of 2018 on Tuesday, 13 November 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Evotec partner Facio Therapies (“Facio”) announced today that oral treatment with one of Facio’s lead candidates results in significant reduction of the human muscle-toxic DUX4 protein in mice engrafted with human FSHD-affected muscle cells. Facio is the first in the FSHD field to achieve proof of principle in an animal model (“in vivo”).

NCL foundation announces today that together with the biotechnology Company Evotec AG it supports a three-year PhD programme for research into juvenile neuronal ceroid lipofuscinosis (NCL). Under scientific supervision by Dr Guido Hermey (Hamburg University), the PhD programme will be based in the facilities and laboratories of Evotec AG. 

Evotec AG and Ferring Pharmaceuticals today announced a strategic research alliance to discover and develop new small molecule therapies to treat patients living with fertility and gynaecological conditions.

Evotec AG announced today that the Company will receive a $ 6 m payment from Celgene following Celgene’s decision to expand the collaboration to include additional cell lines. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’ symptoms and there is a huge unmet medical need for therapeutic modalities that slow down or reverse disease progression.

Evotec AG announced today that it has established an initiative with Sanofi through the launch of a newly created BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas.

MaRS Innovation announced today the second project to be developed under their LAB150 partnership with Evotec. The project aims to develop a novel therapeutic approach to treat glaucoma, an irreversible neurodegenerative disease of the optic nerve which can lead to blindness. This project is derived from a decade of research investigating the molecular pathways underlying tissue damage and repair in the eye in the laboratory of Dr. Jeremy Sivak, Senior Scientist at UHN’s Krembil Research Institute, in Toronto.

In this 7th DDup issue, we delve into the unique new kidney platforms poised to change the trajectory of kidney disease research and therapeutics development.

Evotec AG and  Almirall, S.A. today announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signalling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis.

Evotec AG announced today that Evotec and Celgene Corporation (“Celgene”) have entered into a third long-term strategic drug discovery and development partnership in the field of targeted protein degradation. In this collaboration, Evotec and Celgene will leverage Evotec’s Panomics platform in order to identify drug targets which are traditionally difficult to track. Evotec’s Panomics platform applies in particular high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates on the basis of comprehensive cell biological profiles.

Evotec AG announced today that its shares will be included in the MDAX as of 24 September 2018 as announced by Deutsche Börse on 05 September 2018. This dual listing of the Evotec shares in both TecDAX and MDAX results from the rule changes regarding the inclusion of companies in the MDAX, SDAX and TecDAX.

Evotec AG announced today that its management will be presenting and attending at the following conferences:

Goldman Sachs 8th Annual Biotech Symposium, London, UK

J.P. Morgan Cazenove Pan-European Small/Mid Cap Conference, London, UK

Morgan Stanley 16th Annual Global Healthcare Conference, New York, USA

Baader Investment Conference, Munich, Germany

Berenberg and Goldman Sachs Seventh German Corporate Conference, Munich, Germany

Cantor Global Healthcare Conference 2018, New York, USA

Evotec AG today announced that CHDI Foundation, Inc. (“CHDI”) has extended its collaboration with Evotec through to 2023. Over this period, CHDI may fund up to 75 full-time scientists at Evotec. The collaboration was initiated in 2006 and has grown considerably over this period to fully utilise Evotec’s best-in-class integrated neuroscience platform. The extension of this collaboration is a further validation of Evotec’s investment in new technologies and capabilities in support of driving innovative drug discovery collaborations. 

Evotec AG today announced that CENTOGENE AG, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, and Evotec entered into a global strategic collaboration agreement for joint drug discovery projects, developing compounds to treat rare genetic diseases.

Evotec AG today announced a strategic alliance with Novo Nordisk to discover and develop novel small molecule therapies to treat patients suffering from diabetes and obesity as well as co morbidities such as nonalcoholic steatohepatitis (“NASH”), cardiovascular diseases, and diabetic kidney disease.

Evotec AG announced today that Haplogen GmbH (“Haplogen”), a Vienna-based biotechnology company and collaboration partner of Evotec, has entered into a multi-year drug discovery and development collaboration with Bayer AG to identify new therapeutics with applications in pulmonary diseases such as chronic obstructive pulmonary disease (“COPD”).

Evotec AG today reported financial results and corporate updates for the first half of 2018. 

Evotec AG will report its financial results for the first half of 2018 on Thursday, 09 August 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Evotec AG announced today that it completes the repayment of 50% of the € 140 m debt bridge facility within the first year of being granted in context of the Aptuit acquisition in 2017. Effective August 2017, Evotec acquired Aptuit, a partner research organisation for integrated outsourced drug discovery and development, for € 253.2 m in cash. This acquisition was financed through existing cash reserves and a new € 140 m senior debt bridge facility.

Evotec AG announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development for the treatment of chronic cough, resulting in a payment of € 4 m to Evotec.

Evotec AG today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious disease research portfolio, has been successfully closed with effect from 01 July 2018. 

Evotec AG today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached its second beta cell therapy milestone, resulting in a payment of € 3 million to Evotec. This milestone was triggered after Evotec met pre-agreed critical success criteria for a potential manufacturing process for generation of human induced pluripotent stem cell (iPSC)-derived beta cells, including the demonstration of upscaling potential and suitability of the cell product for encapsulated beta cell function in diabetes models.

Evotec AG today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2018 with the required majorities.

Evotec AG today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives. This successfully seals the exclusive negotiations between the two companies and completion of the required legal social process, initiated on 08 March 2018.

Evotec AG announced today the formation of the LAB591 academic BRIDGE with Arix Bioscience plc (“Arix”, London Stock Exchange: ARIX ) and the Fred Hutchinson Cancer Research Center (“Fred Hutch”). LAB591 aims to accelerate research discoveries at Fred Hutch and leverage these discoveries to form new companies focused on cancer and infectious disease drug development.

Evotec AG announced today that the Company will receive a $ 6 m payment from Celgene following Celgene’s decision to expand the collaboration to include additional cell lines. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases.

Evotec AG today announced that it has expanded its iPSC platform through a licence agreement with ID Pharma. The non-exclusive licence enables Evotec to both work with and differentiate induced pluripotent stem cells (“iPSC”) produced with ID Pharma’s Sendai virus (“SeV”) vector technology.

Evotec AG announced today that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.

Evotec AG today reported financial results and provided corporate updates for the first quarter of 2018.

Evotec AG today announced a strategic collaboration with Carna Biosciences, Incorporated (“Carna”). Carna will access Evotec’s INDiGO platform to accelerate the development of its programme CB-1763, which is being developed for the treatment of blood cancer, through to the submission of an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration.

Evotec AG announced today that its management will be presenting at the Deutsche Bank 43rd Annual Health Care Conference in Boston, USA, at the Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, USA, at the Berenberg USA Conference 2018 in Tarrytown, USA, at the Jefferies 2018 Global Healthcare Conference in New York, USA, and at the dbAccess Berlin Conference in Berlin, Germany.

Evotec AG today announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene editing, thereby complementing and expanding its existing service offering in the CRISPR gene editing space. The new licence from ERS Genomics Limited complements and expands Evotec’s existing CRISPR licences through the Broad Institute with gene editing technology from Emmanuelle Charpentier and others.

Evotec AG will report its financial results for the first quarter of 2018 on Wednesday, 09 May 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for the fiscal year 2018. The conference call will be held in English.

Five years after initiating our endometriosis alliance with Bayer, we draw some very important lessons from one of our key performance-based alliances – and share our insights.

Evotec AG announced today that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive condition that affects approximately 176 million women worldwide.

Evotec AG announced today a strategic collaboration with Petra Pharma Corporation (“Petra”). Through the collaboration, Petra will access Evotec’s INDiGO platform to accelerate the development of its lead programme Petra-01, which is being developed for a range of oncological indications, through to the submission of an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration by the close of 2018.

Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2017.

Evotec AG has launched its accelerated drug development service INDiGO®. With the launch of INDiGO®, Evotec’s expertise and capabilities are uniquely combined under one roof to deliver better drug candidates to patients faster and more efficiently than standard industry approaches. 

Evotec AG will report its financial results for 2017 on Wednesday, 28 March 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2018. The conference call will be held in English.

Evotec AG today announced that it has entered into a research collaboration with the Center for Regenerative Therapies TU Dresden ("CRTD") to discover novel small molecule candidates for retinal diseases. 

Evotec AG announced today that LAB282, the £ 13 m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec, is celebrating its first year of operation after successfully accelerating 12 drug discovery and development projects at the University.

Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced today that they entered into a global non-exclusive IP licensing agreement with Evotec

Evotec AG announced today that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues of EUR 2.00 m to Evotec.

Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, today announced that the first patient has been dosed in the phase 1 clinical programme of CT7001

Evotec AG announced today that its management will be presenting at upcoming investor conferences

Evotec AG today reported financial results and corporate updates for the first nine months of 2017.

Evotec AG today announced a strategic collaboration on microfluidics technology including induced pluripotent stem cell ("iPSC") differentiation with leading academic institutions in the UK and Italy to accelerate the discovery of novel drugs to treat kidney diseases.

Evotec AG will report its financial results for the first nine months of 2017 on Wednesday, 08 November 2017. 

Evotec AG and TESARO, Inc. today announced a three-year integrated drug discovery collaboration to discover and develop novel small molecule product candidates against an undisclosed immuno-oncology (IO) target. 

Evotec AG announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec.

Evotec AG and Exscientia Ltd ("Exscientia") today announced that Evotec has made a EUR 15 m investment to take a minority stake in Exscientia.

Evotec AG and MaRS Innovation ("MI") today announced the launch of "LAB150".

Evotec AG and the European Investment Bank ("EIB") announced today that the EIB has granted Evotec an unsecured loan facility of up to EUR 75 m to support Evotec's Innovate strategy.

Evotec AG and ABIVAX today announced a strategic collaboration to discover and develop novel treatments for multiple serious viral infectious diseases.

Evotec AG announced today that its management will be presenting at upcoming investor conferences.

Evotec AG today announced that, effective mid-August 2017, it has successfully completed the acquisition of Aptuit as announced in detail on 30 July 2017.

Evotec AG today reported financial results and corporate updates for the first half of 2017.

Evotec AG today announced a strategic collaboration on induced pluripotent stem cell ("iPSC") technology with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, ScreeningPort.

Evotec AG will report its financial results for the first half of 2017 on Thursday, 10 August 2017.

Evotec AG and Aptuit announced today that they have entered into a definitive agreement under which Evotec will acquire Aptuit for $ 300 m.

Evotec AG announced today an integrated drug discovery collaboration with STORM Therapeutics ("STORM") to develop new small molecule epigenetic drugs for oncology and other therapeutic areas.

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has advanced a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.

Evotec AG announced today that the Company has been awarded a 'Programm für Innovation' ("PROFI") grant for a period of two years from the  Hamburgische Investitions- und Förderbank

Evotec AG today announced a collaboration with Censo Biotechnologies Ltd. ("Censo") to source and provide patient-derived induced pluripotent stem cells ("iPSC") to support Evotec's broad iPSC platform.

Evotec AG announced today that LAB282, the drug discovery BRIDGE between Oxford University, has made its second round of awards to support promising life sciences ideas emerging from the University.

Evotec AG announced today that it will make a strategic investment as part of Facio Therapies' ("Facio") 2017 funding round together with Australian, European and North American members of the Facioscapulohumeral dystrophy ("FSHD") community (Total volume: EUR 4.8 m).

Evotec AG was awarded the European Mediscience Award for “Company of the Year”. 

Evotec AG today announced that it has joined the NURTuRE consortium to drive kidney disease
focused drug discovery based on patient derived-data.

Evotec AG today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting, which took place today, with the required majority.

Forge Therapeutics and Evotec present first efficacy data for Lpxc inhibitor in uti model at  ASM MICROBE 2017

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another significant pre-clinical milestone, triggering a payment of approx. EUR 5 m to Evotec for the transition of a programme into pre-clinical development for the treatment of endometriosis.

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at upcoming investor conferences

Evotec AG today reported financial results and corporate updates for the first quarter of 2017.

Evotec AG today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached an important milestone, triggering a payment of EUR 3.0 m to Evotec, for achieving pre-clinical proof-of-concept.

Evotec AG today announced that its partner Forge Therapeutics ("Forge") has received a research award from CARB-X (Combating Antibiotic Resistant Bacteria) of $ 8.8 m to advance its novel Gram-negative antibiotic programme targeting LpxC for the treatment of bacterial infections.

Evotec AG today announced its financial results and corporate updates for the fiscal year ended 31 December 2016.

Evotec AG and Business France today released their short film about Evotec’s research site in Toulouse, France, under the headline: “Evotec found Business in France – Great story, short film”.

Evotec AG is pleased to announce that LAB282, the £ 13 m (over EUR 15 m) drug discovery partnership with Oxford University, has made its first wave of awards, backing projects targeting cardiovascular diseases and infectious diseases.

Evotec AG today announced that it resolved on a capital increase from its authorised capital against cash. Evotec will issue 13,146,019 new shares to Novo A/S (Denmark). Novo A/S is the independent holding company for the Novo Group.

Evotec AG today announced that Cyprotex, a company wholly owned by Evotec AG, has completed the relocation of its UK operations from Macclesfield to Alderley Park.

Evotec AG today announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan.

Evotec AG and MaRS Innovation today announced the launch of Fibrocor Therapeutics LP ("Fibrocor"), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases. 

Evotec AG today announced a promising research result in the field of picornaviruses published in a scientific article by Dr Thijn Brummelkamp, the co-founder of Haplogen GmbH, a biotech company based in Vienna, Austria, that develops antiviral therapeutics in a co-owned partnership with Evotec.

Evotec AG announced today that it will extend its existing relationship with Eternygen GmbH ("Eternygen") by becoming an investor in addition to being a pre-clinical drug discovery partner. 

Evotec AG announced today that Evotec and Celgene Corporation have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases.

Evotec AG today announced the successful closing of the acquisition of 100% shares in Cyprotex PLC, a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in the UK.

Evotec AG today announced a strategic alliance with Forge Therapeutics, Inc. ("Forge") to advance its novel Gram-negative antibiotic programme targeting "LpxC" for the treatment of bacterial infections including those caused by drug resistant 'superbugs'.

Evotec AG today announced the signing of a set of collaboration agreements with the life science business of Merck, which will combine Merck's portfolio of genome editing technologies with Evotec's versatile screening platforms and disease expertise.

Evotec AG today announced a novel strategic partnership with the University of Oxford, Oxford University Innovation Ltd, OUI (the university's research commercialisation company) and Oxford Sciences Innovation, OSI (the world's largest IP investment company dedicated to a single university) aimed at accelerating the translation of basic biomedical research from Oxford into new therapeutics.

Evotec AG today reported financial results and corporate updates for the first nine months of 2016.

Evotec AG today announced that it has made an offer to acquire Cyprotex PLC ("Cyprotex", AIM: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK.

Evotec AG today announced a collaboration with UCB to provide a broad range of in vitro pharmacology services.

Evotec AG announced today that in line with its strategy to participate in promising corporate formations it will deepen its already existing relationship with Carrick.

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another key pre-clinical milestone for the transition of a project from the alliance portfolio into pre-clinical development.

Evotec AG today announced a multi-target collaboration with C4X Discovery Holdings plc ("C4XD").

Evotec AG announced today that the Company has entered into a research collaboration with Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research ("Inserm").

Evotec AG today announced that Evotec and Bayer have entered into a five-year, multi-target research partnership in kidney disease. 

Evotec AG today reported financial results and corporate updates for the first half of 2016.

Evotec AG announced today that it has reached a milestone from Bayer for the progression of a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.

Evotec AG announced today a collaboration with Antibiotic Research UK ("ANTRUK") to identify alternative means of treating infections that are resistant to currently available antibiotics.

Evotec AG announced today that the Company has entered into a non-exclusive licence agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology.

Evotec AG announced today that the investment company Ellersbrook GmbH & Co. KG, ("Ellersbrook"), Germany, will invest into Evotec's internal TargetNASH programme. 

Evotec AG today announced that Genentech, a member of the Roche Group, has extended its integrated drug discovery alliance with Evotec for a further three years to discover novel small molecule therapeutics.

Evotec AG today reported financial results and corporate updates for the first quarter of 2016.

Evotec AG and Exscientia Ltd (Dundee, UK) today announced a collaboration with the objective to discover and develop first-in-class bispecific small molecule immuno-oncology therapies.

Evotec AG today announced a multi-year compound management agreement with Pierre Fabre Laboratories, the 2nd largest private French pharmaceutical group.

Evotec AG today announced the formation of a spin-off company in the field of nanoparticle-based therapeutics to treat immunological disorders.

Evotec AG today announced its financial results for the fiscal year ended 31 December 2015.

Evotec AG today announced the achievement of a key pre-clinical milestone in the ongoing alliance with its research partner Padlock Therapeutics, Inc. ("Padlock").

Evotec AG today announced that it has been awarded a research grant from The Michael J. Fox Foundation ("MJFF") to further develop Evotec's TargetaSN (Targetalpha-synuclein) programme for the treatment of Parkinson's disease.

Evotec AG today announced the achievement of an important milestone in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. ("Janssen") for the transition of a project into further drug discovery process.

Evotec AG today announced an EVT Execute collaboration aimed at providing a complete solution to UCB's global sample management requirements.

Evotec AG today announced an extension of an existing collaboration with Spero Therapeutics, based in Cambridge, Massachusetts, aimed at discovering and developing new and ground-breaking therapeutics for Gram-negative bacteria to treat serious infections and address the growing threat to global public health resulting from antibiotic resistance.

Evotec AG announced today that its multi-target collaboration with Bayer HealthCare has reached two important pre-clinical milestones for the transition of two projects from the alliance portfolio into late-stage discovery and pre-clinical development for the treatment of endometriosis.

Evotec AG today announced an EVT Execute collaboration with Beyond Batten Disease Foundation aimed at discovering and developing new treatments for juvenile Batten disease, a rare, fatal autosomal recessive neurodegenerative disorder. 

Evotec AG today announced it has entered into a multi-year compound management agreement with the U.S. National Cancer Institute, Department of Health and Human Services. 

Evotec AG today announced that it increases its financial guidance for the current year. 

Evotec AG today announced that it has signed an agreement on a four-year research collaboration with Pfizer Inc.

Evotec AG today announced that CHDI Foundation, Inc. has extended and expanded its collaboration with Evotec through to August 2018.

Evotec AG today reported financial results and corporate updates for the first half of 2015.

Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, today announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies.

Evotec AG and Sanofi today announced a strategic collaboration in the field of diabetes.

Evotec AG today announced that it has become part of a research initiative between a newly established for-profit company of the Gladstone Institutes called Cure Network Ventures, Inc. and Dolby Family Ventures.

Evotec AG  was updated today by its partner Roche on the initial results of the Phase IIb trial with Sembragiline, a MAO-B inhibitor for the treatment of Alzheimer's disease.

Evotec AG and Facio Therapies announced today that they have entered into an agreement aimed at the identification of compounds showing activity as a potential treatment to stop the progression of FSHD, a muscle wasting disease.

Evotec AG today announced it has entered into a multi-target screening collaboration on several ion channel targets, with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan.

Evotec AG today announced its financial results for the fiscal year ended 31 December 2014.

Evotec AG today announced that a definitive agreement for a major multi-component strategic alliance over the next five years has been signed with Sanofi.

Evotec AG and Second Genome, Inc. today announced a collaboration in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases.

Evotec AG today announced a research collaboration with C4X Discovery Holdings plc to optimise Orexin-1 selective inhibitors discovered through C4XD's unique NMR technology.

Evotec AG today announced the achievement of several small, but very important milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the identification and selection of novel targets from Evotec's TargetAD database and for the transition of targets into the drug discovery process.

Evotec AG and Padlock Therapeutics, Inc. announced today that they have successfully completed an initial goal in a programme focused on developing inhibitors of protein-arginine deiminases and have further extended the collaboration that was first signed in January 2014.

Evotec AG today announced a research collaboration with the laboratories of Prof. Roger Briesewitz at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

Evotec AG disclosed today that it achieved multiple milestones in ongoing alliances with its strategic research partners.

Evotec AG announced today that it has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years.

Evotec AG today reported financial results and corporate updates for the first nine months of 2014.

Evotec AG announced today that its multi-target collaboration with Bayer HealthCare has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis.

Evotec AG announced today that it has entered into three novel research projects for the treatment of Multiple Sclerosis supported by research funds from the German Federal Ministry of Education and Research.

Evotec AG announced today after careful evaluation that it will take legal steps against Israel-based Andromeda Biotech, Ltd. to recover all Evotec claims and potential damages that result from recent incidents in relation to DiaPep277®.

Evotec AG and the Jain Foundation Inc. today announced that they have further extended and expanded the collaboration first signed in 2012 and extended last year.

Evotec AG today announced that CHDI Foundation, Inc. has extended and restated its collaboration with Evotec through 2017.

Evotec AG was informed that US company Hyperion Therapeutics, Inc. is terminating the development of DiaPep277® for newly diagnosed Type 1 diabetes.

On Friday, the motor neuron research group took on the ALS Ice Bucket Challenge to help raise awareness for this rapidly progressive neurodegenerative disease.

Evotec AG today announced the start of a multi-year compound management agreement between Evotec (US) Inc. and Medicines for Malaria Venture in support of MMV's Malaria and Pathogen Box initiatives.

Evotec AG today reported financial results and corporate updates for the first half of 2014.

Evotec AG today announced the successful achievement of the first milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the identification and selection of three selected targets from the TargetAD database.

Evotec AG today announced the publication of its fifth DDup edition.

Evotec AG announced today an exclusive strategic collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in several disease areas through the combination of the relevant platforms of both organisations for internal and external drug discovery projects.

Evotec AG was awarded the European Mediscience Award for best communication at a celebratory dinner on Thursday, 19 June 2014, in London. 

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 1.0 m to Evotec.

Evotec AG today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting.

Evotec AG today announced the acquisition of all shares in Euprotec Ltd, a UK-based specialist contract research organisation.

Evotec AG today reported financial results and corporate updates for the first quarter of 2014.

Evotec AG and Eternygen GmbH, a privately owned biopharmaceutical company, today announced a drug discovery collaboration to develop novel small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec's technology platform and broad expertise in drug discovery and pre-clinical development.

Evotec AG today announced the successful achievement of a milestone in its biomarker alliance with Roche.

Evotec AG announced today a research collaboration and licensing deal with Debiopharm GroupTM Lausanne, Switzerland.

Evotec AG today announced that it has entered into a research alliance with Panion Ltd, a subsidiary of Convergence Pharmaceuticals Holdings Ltd. Convergence is a UK company focused on the development of novel, high value analgesics to treat chronic pain.

Evotec AG today announced its financial results for the fiscal year ended 31 December 2013, which are in line with the revised expectations communicated in the fourth quarter 2013.

Evotec AG today announced the acquisition of the Germany-based Bionamics GmbH.

Evotec AG today announced a research collaboration, TargetDBR (DNA Break Repair), with the laboratories of Prof. Peter Glazer and Prof. Ranjit Bindra at Yale School of Medicine.

Evotec AG today announced that it is adjusting its guidance regarding Group revenues.

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in November triggering revenues of € 4.0 m to Evotec.

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today reported financial results and corporate updates for the third quarter and first nine months of 2013 ending 30 September 2013.

Evotec AG today announced a collaboration with the Johnson & Johnson Innovation Center in California to identify new targets for Alzheimer's disease drug discovery and development.

Evotec AG announced today that it has entered into an integrated research collaboration with The Leukemia & Lymphoma Society. 

Evotec AG today announced that it has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with UCB in the field of immunology.

Evotec AG today announced that it has signed an agreement with AstraZeneca in the field of kidney diseases.

Evotec AG today announced the publication of its fourth DDup edition.

Evotec AG announced today that its R&D Day 2013 will take place on 22 October 2013 in New York City, USA. 

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of EUR 4.0 m to Evotec.

Evotec AG today announced a second research collaboration, TargetEEM, with the laboratory of Doug Melton, Xander University Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Harvard Stem Cell Institute Scientific Co-Director and Howard Hughes Medical Institute Investigator.

Evotec AG  today announced that its research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of € 2.0 m to Evotec.

Evotec AG announces today the publication of a DDup Special Edition, which focuses on its drug discovery service offering.

Evotec AG today announced a strategic partnership with the Harvard Stem Cell Institute to identify compounds that prevent or slow down the loss of motor neurons, which is characteristic of the human disease amyotrophic lateral sclerosis.

Evotec AG today announced a 9.9% increase of its share capital. 

Evotec AG and the Jain Foundation today announced that they have extended and expanded their research collaboration leveraging Evotec's assay development and screening capabilities to support the Jain Foundation's goals of understanding and curing dysferlinopathy.

Evotec AG today reported financial results and corporate updates for the first half of 2013.

Evotec AG today announced that Evotec and Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, have entered into a research collaboration with the objective of leveraging Evotec's advanced chemical proteomics services to support compounds in development at Dow AgroSciences.

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in June triggering revenues of EUR 1.5 m to Evotec.

Evotec AG today announced that it will close its Chemistry Operations in Thane, India.

Shareholders of Evotec AG today approved the actions of the members of the Management Board and the Supervisory Board for the fiscal year 2012 at the Annual General Meeting.

Evotec AG today announced a research collaboration with Harvard University aimed at discovering and developing novel anti-bacterial agents based on a highly validated target family involved in bacterial cell wall biosynthesis.

The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG today announced a research collaboration aimed at discovering and commercialising novel cancer treatments based on epigenetic drug mechanisms.

Evotec AG today announced that Evotec (US) Inc. has executed a multi-year lease on a facility specifically designed to expand the offering of its Compound Management Services on the East Coast of the United States.

Evotec AG today announced an auspicious step in research from Harvard University.

Evotec AG today announced that it has extended its drug discovery alliance with Genentech, a member of the Roche Group, for three additional years.

Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2012.

Evotec AG today announced that Dr Werner Lanthaler, Chief Executive Officer of Evotec, will resume his role as Chief Executive Officer of the Company with immediate effect after a period of leave due to health reasons.

Evotec AG today announced that a compound identified and optimised in a research collaboration with Ono Pharmaceutical Co., Ltd. has been nominated to enter pre-clinical development, leading to the payment of an agreed milestone.

Evotec AG today announced that it has entered into a strategic partnership with Yale University.

Evotec AG today announced that it has expanded the scope of its collaboration with MedImmune, the global biologics arm of AstraZeneca, after hitting a key milestone.

Evotec AG today announced the acquisition of all shares in Cell Culture Service GmbH, a Hamburg-based company which supports the cell culture needs of a world-wide customer base of biotech and Pharmaceutical companies.

Evotec AG today announced that Evotec and Apeiron Biologics have entered into a research collaboration with the objective of developing immunomodulatory lead compounds for the treatment of cancer.

Evotec AG today announced that it has entered into a license agreement with Janssen Pharmaceuticals, Inc. regarding its NR2B subtype selective NMDA-antagonist portfolio for development against diseases in the field of depression.

Evotec AG announced today that it has entered into a collaboration with Probiodrug AG, a privately owned biopharmaceutical company focused on the development of innovative drugs for the treatment of major age related diseases.

Evotec AG today announced that it has received CIR accreditation for a three-year period from the French Ministry of Higher Education and Research.

Evotec AG and Haplogen GmbH have signed a collaboration agreement to discover and develop small molecules against viral infectious diseases.

Evotec AG today reported financial results and corporate updates for the third quarter and first nine months of 2012 ending 30 September 2012.

Evotec AG today announced that CHDI Foundation, Inc., a privately-funded not-for-profit research organisation dedicated to developing therapies for Huntington's disease, has extended its collaboration with Evotec until the end of 2015.

Evotec AG announced today that Dr Werner Lanthaler, Chief Executive Officer of Evotec, was awarded the prize 'Turnarounder of the Year 2012'.

Evotec AG  today announced that it has received a pre-clinical milestone from its Drug Discovery Collaboration with Novartis.

Evotec AG today announced that Dr Werner Lanthaler, CEO of Evotec, will temporarily stand down from his role within the company due to health reasons.

Evotec AG today announced that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.

Evotec AG and Aspireo Pharmaceuticals Limited an Israeli biopharmaceutical company focused on the development of a novel somatostatin analogue, announced today that they have entered into a strategic advisory agreement for support in the development and partnering of Aspireo's Somatoprim.

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.5 million to Evotec.

Evotec AG today announced that Evotec has entered into a multi-year compound management agreement with the National Institutes of Health, Department of Health and Human Services, for the operation of a Small Molecule Repository.

Evotec AG today reported financial results and corporate updates for the second quarter and first half of 2012 ending 30 June 2012.

Evotec AG today announced that it has licensed to Janssen Pharmaceuticals, Inc. a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells. 

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 4.0 million to Evotec.

Evotec AG is proud to announce the addition of Agilent Technologies' RapidFire Mass Spectrometry analysis capabilities to their High Throughput Screening facilities in Hamburg.

Evotec AG today reported financial results and corporate updates for the first quarter of 2012.

Evotec AG and 4-Antibody AG today announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service.

Evotec AG today announced that Evotec has entered into a multi-year compound management agreement with the United States EPA. 

Evotec AG and Conba Pharmaceutical Co., Ltd. announced today the grant of a development and marketing license on EVT 401, a selective, small molecule P2X7 antagonist, for human indications with exception of ophthalmological, chronic obstructive pulmonary disease and endometriosis in China.

Evotec AG today announced that it has extended and expanded its medicinal chemistry collaboration with Active Biotech AB, to further advance an existing programme, which has entered the lead optimisation phase.

Evotec AG today announced the publication of its second edition of DDup, which focuses on neurodegeneration diseases, major disorders with inadequate standards of care. 

Evotec AG today reported financial results and corporate updates for the year ended 31 December 2011.

Evotec AG and IR Pharma today announced that they have entered into an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of Respiratory Diseases.

Evotec AG today announced the completion of the squeeze-out process to acquire all of the remaining shares of DeveloGen AG from its minority shareholders.

Evotec AG today announced a second strategic alliance with Harvard University, this time including Brigham and Women's Hospital aimed at discovering and developing new biomarkers and treatments in the field of kidney disease.

Evotec AG today announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 2.5 million to Evotec.

Evotec AG today reported financial results and corporate updates for the first nine months of 2011.

Evotec AG today announced the achievement of specific success criteria in a multiple target drug discovery collaboration with Shionogi & Co Ltd. and the receipt of two milestone payments.

 Evotec AG and Apeiron Biologics AG today announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy.

Evotec AG today announced that it has entered into a second multi year, multi target integrated drug discovery collaboration with UCB in the field of immunology.

Evotec AG today announced that it has signed a Share Purchase Agreement to acquire the remaining 30% of equity of its Joint Venture with DIL Limited, India for €1.7M.

Evotec AG and Roche AG announced today that they have entered into an exclusive worldwide agreement for the development and commercialization of Evotec's MAO-B inhibitor in patients with Alzheimer's disease.

Evotec AG  today announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 4 million to Evotec.

Evotec AG today announced that it has entered into a world-wide license and collaboration agreement with a top tier animal health company that intends to develop the proprietary Evotec compound EVT401, a selective, small molecule P2X7 antagonist, in the companion animal market.

Evotec AG today reported financial results and corporate updates for the first half of 2011.

Evotec AG today announced that it has entered into a three year integrated drug discovery collaboration with UCB to identify small molecule modulators of priority biological targets, selected by UCB, involved in CNS disorders.

Evotec AG today announced the achievement of specific success criteria in an ion channel research collaboration with Ono Pharmaceutical Co., Ltd. and the receipt of a milestone payment. 

Evotec AG and Roche today announced a collaboration in novel protein-activity based biomarkers for Roche's oncology drugs under development.

Evotec AG today announced that it has entered into a medicinal chemistry collaboration with Active Biotech AB, following the successful conclusion of a High Throughput Screening campaign to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.

Evotec AG and Galapagos NV today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, a Galapagos Company. 

Evotec AG today announced that a back-up compound in its strategic alliance with Boehringer Ingelheim has advanced into a Phase I clinical trial. Evotec will receive a milestone payment of EUR 2.0 million.

Evotec AG today announced that it has entered into a strategic alliance with PsychoGenics Inc. to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies.

Evotec AG and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type selective NMDA antagonist EVT 101.

Evotec AG today reported financial results and corporate updates for the first quarter of 2011.

Evotec AG today announced that its research alliance with Boehringer Ingelheim has achieved a twelfth milestone triggering a payment of EUR 2.0 million to Evotec.

Evotec AG today announced that it has completed the acquisition of Kinaxo Biotechnologies GmbH, a privately held drug discovery alliance company supporting the development of targeted drugs.

Evotec AG today reported financial results and corporate updates for the year ended 31 December 2010.

Evotec AG today announced the establishment of a research collaboration with Harvard University and the Howard Hughes Medical Institute aimed at discovering and developing new  treatments in the field of diabetes.

Evotec AG today announced that it has entered into a collaboration with ChemBridge, to further enhance its screening library.

 Evotec AG today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs.

Evotec AG today announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and Protease targets involved in various CNS and Metabolic diseases.

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.0 million to Evotec.

Evotec AG announced today that on 30 December 2010 it filed a Form 15F with the Securities and Exchange Commission to deregister and terminate its reporting obligations under the U.S. Securities Exchange Act of 1934 for its American Depositary Shares and its ordinary shares underlying the ADSs.

Evotec AG today announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune, in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells.

Evotec AG today announced that it has signed within the "NEU²-Consortium" framework and partially funded by the Federal Ministry of Education and Research, an agreement with Merck KGaA, Darmstadt, Germany, to develop pre-clinical candidates for an undisclosed neurological disease.

Evotec AG today reported financial results and a corporate update for the first nine months of 2010.

Evotec AG today announced that it has entered into a license and collaboration agreement with Zhejiang Jingxin Pharmaceutical Co., Ltd for EVT 201, a novel potential treatment for insomnia.

Evotec AG today announced that it has entered into a collaboration with Apeiron Biologics AG, to initially identify small molecule modulators of DREAM, a novel target involved in perception of various pain mechanisms.

Evotec AG today announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd., to identify small molecule modulators of various protein-protein interaction targets.

Evotec AG today announced that it has entered into a collaboration with Almirall S.A., to identify small molecule modulators of an ion channel target, selected by Almirall, involved in respiratory diseases.

Evotec AG today announced the Closing of the agreement to acquire DeveloGen as announced in detail on 14 July 2010.

Evotec AG today reported financial results and corporate updates for the first half of 2010.

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.5 million to Evotec.

Evotec AG today announced the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company engaged in the discovery of novel therapeutic approaches for the treatment of metabolic and endocrine disorders, for up to € 14m in shares plus performance-related deferred payments.

Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101.

Evotec AG today announced that it has achieved a milestone as part of its research alliance with Boehringer Ingelheim and will receive a payment of EUR 2.5 million.

Evotec AG today announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials.

Evotec AG today reported financial results and corporate updates for the first quarter of 2010.

Evotec AG today announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group, to discover novel small molecule therapeutics. 

Evotec AG today announced that it will receive funding of up to EUR 1.5 million from the German Federal Ministry of Education and Research to advance its H3 receptor antagonist programme into the clinic.

Evotec AG today reported financial results and corporate updates for the year ended 31 December 2009.

Evotec AG has been named the M&A Advisor Healthcare Turnaround Company of the Year for the development and implementation of the 'Evotec 2012 - Action Plan to Focus and Grow'.

Evotec AG today announced that it has signed an agreement with Hypha Discovery Ltd. Under the terms of the agreement, Evotec will be able to provide its screening clients with access to Hypha’s MycoDiverse™ natural product collection for use as part of its hit and lead identification services.

Evotec AG today announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.

Evotec AG today announced two positive aspects that strengthen its integrated product development in treatment-resistant depression in its strategic alliance with Roche.

Evotec AG today announced that it has extended its research agreement with Cubist Pharmaceuticals, Inc. to the end of 2010.

Evotec AG today announced that it has signed an agreement with Vifor Pharma. 

Evotec AG today announced the extension of its collaboration with CHDI Foundation, Inc. through to the end of 2012.

Evotec AG today announced that it has received a milestone payment from Ono Pharmaceutical Co., Ltd. from its research collaboration aimed at identifying novel inhibitors for a protease target.

Evotec, a leading provider in the discovery and development of novel small molecule drugs, today announced that it has been granted up to € 2.5 m in research funds from the BMBF, within the Neu2 consortium, to advance research and development activities on the target Serine Racemase for potential use in neuroprotection.

Evotec AG today reported results and corporate updates for the third quarter and nine months ended September 30, 2009.

Evotec AG a leading provider in the discovery and development of novel small molecule drugs today announced that it plans to voluntarily delist its American Depositary Shares from the NASDAQ stock market and concentrate its share trading on the recently re-entered TecDAX platform.
 

Evotec AG today announced that it has extended the research collaboration with Boehringer Ingelheim for a further 4 years.

Evotec AG today announced that it has achieved another milestone in its research collaboration with Boehringer Ingelheim.

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs and DiscoveRx Corporation, a premier provider of innovative cell based assay solutions, today announced a co-marketing agreement for the screening of GPCR's and other targets.

Evotec AG today announced that it has extended its current research collaboration with Ono Pharmaceutical Co., Ltd. and initiated a new discovery collaboration.

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced that the company has achieved an important milestone with Cardioxyl Pharmaceuticals under a collaboration agreement for the compound, CXL-1020, that has successfully moved into clinical testing.

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced that it has entered into a research agreement with Biogen Idec, a leading biopharmaceutical company headquartered in Cambridge, Mass., USA.

Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today the Phase I clinical study initiation for EVT 103, a small molecule NR2B-selective NMDA receptor antagonist.

Evotec AG announced today that the acquisition of the controlling majority stake of Research Support International Private Limited has been successfully completed and that RSIPL is a 70%, majority owned subsidiary of Evotec as of August 31, 2009.

Evotec AG today reported results and corporate updates for the second quarter 2009.

Evotec AG and DIL Limited, India, announced today the signing of a definitive agreement to acquire a 70% controlling majority stake of the drug discovery service company RSIPL for EUR 2.8 million in cash, a portion of which includes a potential earn-out.
 

Evotec AG will report its financial results for the first half of 2009 on Friday, August 7, 2009.
 

Evotec AG today announced that a further research milestone, leading to payments to Evotec, has been successfully achieved in its drug discovery collaboration with Boehringer Ingelheim.

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced a collaboration with Alios Biopharma, Inc in the area of high throughput screening.

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced that it has entered into a research agreement with Cubist Pharmaceuticals, Inc., a leading acute care biopharmaceutical company located in Lexington, Mass., USA.

Evotec-RSIL Ltd. announced today that Ferrer Grupo, the Spanish pharmaceutical and healthcare company has extended their ongoing collaboration.

Evotec AG today announced the successful completion of the first Phase I study with its P2X7 receptor antagonist EVT 401.

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced the expansion of its ion channel capabilities with the addition of unique, ion channel focused libraries and additional electrophysiology screening platforms. 

Evotec AG today reported results and corporate development updates for the first quarter ended March 31, 2009.

Evotec AG today announced that the Company will acquire the zebrafish screening operations of Summit Corporation plc, including operations in Abingdon, UK, and Singapore, for £ 0.5 million in cash.

Evotec AG announced today that in the context of its Evotec 2012 - Action Plan to Focus and Grow, the Company is re-engineering its drug discovery and development operations to improve efficiency and realize further cost saving potential.

Evotec AG announced today that the Supervisory Board proposes at the next Annual General Meeting to be held on June 4, 2009 the election of Dr Walter Wenninger as new member of the Company's Supervisory Board.

Evotec AG today announced the results of a Phase II proof-of-concept study investigating the potential of EVT 302, a reversible and highly selective inhibitor of monoamine oxidase B, as an aid to smoking cessation. 

Evotec AG today announced that it will restructure to focus on core value programs and significantly reduce its operating costs.

Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today reported financial results for the year ended December 31, 2008.

Evotec AG and Roche announced today that they have entered into an agreement for Phase II clinical development of EVT 101 in patients with treatment-resistant depression.

Evotec AG announced today the appointment of Dr. Werner Lanthaler as Chief Executive Officer of the Company, effective immediately.

Joern Aldag, President and Chief Executive Officer of Evotec OAI, commented: "Following a successful collaboration in the development of our EVOscreen® uHTS system, Novartis has chosen Evotec OAI to support their lead discovery efforts. We are delighted that one of the world's leading R&D organisations has chosen our expertise in drug discovery and our technology platform in this critical area of research."